Circulating Tumor Cells as Diagnostic Tools and Therapeutic Targets by Marshall, Jocelyn Rose
  
 
CIRCULATING TUMOR CELLS AS DIAGNOSTIC TOOLS AND 
THERAPEUTIC TARGETS 
 
 
 
 
 
 
 
 
A Dissertation 
Presented to the Faculty of the Graduate School 
of Cornell University 
In Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
 
 
 
 
 
 
by 
Jocelyn Rose Marshall 
January 2017
  
 
 
 
 
 
 
 
 
 
 
 
© 2017 Jocelyn Rose Marshall
  
CIRCULATING TUMOR CELLS AS DIAGNOSTIC TOOLS AND 
THERAPEUTIC TARGETS 
 
Jocelyn Rose Marshall, Ph. D. 
Cornell University 2017 
 
Circulating tumor cells have been a major area of focus for cancer metastasis research 
for the last few decades, and while the majority of progress has mainly centered on the 
isolation and enumeration of CTC for prognostic purposes, researchers are beginning 
to explore additional uses for CTC in the clinical setting. While it is well known that 
CTC counts correlate with prognosis, CTC counts are also being explored as a marker 
for response to therapy. CTC enumerated before and after surgical procedures are 
shedding light on the advantages of minimally invasive techniques.  
CTC characterization has also increased in the past decade. When CTC were first 
reliably isolated, the majority of work focused solely on EpCAM-expressing cells 
found within the blood of patients with late stage cancer. Today, EpCAM-negative 
CTC and CTC expressing mesenchymal markers are under great scrutiny for a 
potentially increased metastatic potential. Moreover, CTC that differ in protein and 
gene expression to the primary tumor have been found elucidating prospective issues 
with drug targets. CTC have been isolated and identified in patients with local tumors 
or even pre-cancerous lesions.  
Here, we present a diagnostic method that uses CTC to prescreen for drug 
susceptibility. This method is then used to show primary CTC sensitivity to a novel 
TRAIL-based immunotherapeutic targeted towards CTC. Peripheral blood samples are 
shown to contain circulating stromal cells believed to migrate alongside CTC and 
 likely alter their survival under shear conditions as well as their drug susceptibility. 
We culminate these studies by conducting the first efficacy study of EST liposomes in 
an immunocompetent breast cancer tumor resection murine model. 
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Chapter 1 
 
Capture and Targeting of Circulating Tumor Cells 
 
Portions of this chapter were adapted from: Marshall'JR,'King'MR.'Selectin4Mediated'Targeting'of'Circulating'Tumor'Cells'for'Isolation'and'Treatment.'In:'Circulating'Tumor'Cells'[Internet].'Hoboken,'NJ,'USA:'John'Wiley'&'Sons,'Inc;'2016'[cited'2016'Oct'20].'p.'267–86.'
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1.1 Introduction 
Circulating tumor cells (CTCs) have provided researchers with a wealth of 
information about metastatic cancer. However, the exact mechanisms of metastasis 
through the bloodstream are not yet definitively known. Mounting evidence indicates 
that CTCs utilize the same pathway through which immune cells are recruited to sites 
of inflammation. This pathway involves a variety of adhesion molecules, including 
those in the selectin family. In this chapter, we discuss how these adhesion molecules, 
namely E-selectin, can be used to recapitulate the early steps of CTC adhesion in vitro 
to achieve capture and characterization of CTCs from patient blood samples. We also 
discuss how this interaction may be exploited to target and kill CTCs in vivo.  
 
1.1.1 Selectin Adhesion 
Cell-cell adhesion is necessary for the maintenance of tissue homeostasis as well as 
communication between cells.  Because of their importance, cell adhesion molecules 
have been the focus of extensive research for decades. In the late 1980s, an important 
group of adhesion proteins, called selectins, were discovered on different cells in the 
vasculature. L-selectin was found on leukocyte membranes; P-selectin was found in 
the granules of platelets, though it was also discovered to be expressed by the vascular 
endothelium; E-selectin was shown to be expressed by inflamed endothelium. All 
three of these proteins facilitate immune cell interactions, including leukocyte 
recruitment to areas of inflammation [1–4]. The selectins were first discovered 
independently using antibodies that inhibited different adhesion interactions, but it was 
quickly discovered that the proteins were related and belonged in the same protein 
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family. Not only are the selectins found within a 300 base pair section of chromosome 
1 [5], but also they have very similar structures. Each selectin protein contains a lectin 
domain, an EGF (epidermal growth factor) repeat domain, a series of complement 
regulatory-like regions, and transmembrane and cytoplasmic domains. Where the 
proteins differ is in the number of complement regulatory-like regions; L-selectin 
having 2, P-selectin 9, while E-selectin has 6 [6]. 
Once the sequence and structure of the selectin molecules were discovered, focus 
transitioned to the function of the molecules. One of the main functions of these 
proteins is to mediate leukocyte recruitment to areas of inflammation, an important 
process for both the innate and adaptive immune systems [7–9]. It is known that this 
pathway has a number of discrete steps: tethering and rolling, activation, firm 
adhesion, and extravasation (Figure 1.1) [10]. The selectin family is important in 
mediating this process, in particular the tethering and rolling steps, while integrins 
have been shown to mediate the fast-to-slow rolling transition as well as firm adhesion 
[8,9,11]. Soon after their discovery, the selectins were shown to bind to 
sialylfucosylated ligands, sialyl Lewis x (sLex) and sialyl Lewis a (sLea). While these 
are the minimum binding structures for the selectins, these carbohydrate groups are 
usually found on a carrier backbone of either a glycoprotein or glycolipid [12,13]. P-
selectin glycoprotein ligand-1 (PSGL-1) is one of the most extensive selectin ligands 
studied, and it is one of the few ligands that has been shown to bind to all three 
selectins [14].   
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The selectins, namely E-selectin, are also important at mediating the hematogenous 
metastasis of many types of cancer. It is believed that cancer cells use a similar 
mechanism to leukocyte adhesion to migrate to distant sites in the body. This 
phenomenon was first studied in detail for colon cancer cells [15–21] but since then 
different types of cancer cells have been shown to adhere to E-selectin including, but 
not limited to prostate [22–24], breast [25–30], lung [31], and pancreatic cancer cells 
[32–35]. The importance of these adhesive interactions in metastasis was solidified 
further when it was discovered that the expression sLex and sLea, two important 
selectin ligands, correlated with survival rate and metastasis [36–41]. Moreover, 
reagents blocking certain glycosylation processes have been shown to inhibit 
metastasis in several in vivo studies [42].   
Figure 1.1. Leukocyte Adhesion Cascade, from [10]. Figure reprinted with permission. 
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Cancer metastasis differs from leukocyte recruitment to areas of inflammation in some 
key ways. First, E-selectin is the major selectin implicated in cancer metastasis, while 
leukocyte recruitment uses a combination of interactions involving all three selectins. 
Colon, gastric, and lung cancer cell lines have been shown to bind to E-selectin, but 
not to P-selectin [17,43]. However, P- and L-selectin have been shown to influence 
cancer metastasis in vivo, as P-/L-deficiency in mice inhibits metastasis [11,13], 
though it may be that these selectins influence the adhesion of platelets and immune 
cells that enable cancer adhesion to endothelium rather than adhering to the cancer 
cells directly [11,13]. Secondly, sLea is found on a number of different cancer types in 
abundance, whereas leukocytes express low to no sLea. Takada, et al. showed that 
some cancer cell lines rely solely on sLea for adhesion to human umbilical vein 
endothelial cells (HUVECs), while others rely heavily on sLex [44]. Also, in a colon 
cancer xenograft study, sLea-expressing cells were shown to generate larger tumors 
when compared to their non-expressing counterparts [41].  The implication is that 
while cancer cells and leukocytes share a number of selectin ligands, such as PSGL-1, 
some cancers express novel ligands, which could serve as a target for anti-cancer 
therapies. One example is hemapoetic cell E-selectin/L-selectin ligand (HCELL), a 
CD44 glycoform, which on cancer cells is expressed on O-glycans, rather than N-
glycans as on hemapoietic progenitor cells, thus demonstrating that HCELL is 
expressed as the variant form of CD44 in cancer [45]. 
Cancer-related inflammation has been the subject of much research, especially relating 
to metastasis.  E-selectin is generally only expressed on cytokine-stimulated 
endothelial cells. Some cancers have been shown to secrete inflammatory cytokines 
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such as Il-1. The Hakomori lab showed that while not all cancer cells have the 
ability to secrete these cytokines, the interaction of cancer cells with platelets could 
induce this secretory ability, thereby promoting inflammation [46]. Moreover, tumors 
are infiltrated by a variety of immune cells, which may contribute to cancer-related 
inflammation [47]. It should also be noted that E-selectin is constitutively expressed 
on the skin and bone marrow endothelium [48].  
 
1.1.2 Circulating Tumor Cells 
CTCs are epithelial cells that have dissociated from the primary tumor and entered the 
blood stream. CTCs were first discovered in 1869 in the blood of cancer patient during 
an autopsy [49]. However, CTCs did not become a major subject of cancer research 
until two decades ago. Most work has centered around the detection and isolation of 
CTCs from blood samples of cancer patients, though in recent years research has 
expanded to the identification of important mutations present in CTCs, EMT 
(epithelial-mesenchymal transition) status of CTCs, and the correlation of CTC count 
with drug efficacy [50–59]. CTCs have been identified in the blood of patients with 
breast [50,53,60–65], lung [66], pancreatic [67], prostate [52,68,69], head and neck 
[51], colorectal [70–72], renal [73,74], gastric [75,76], and bladder cancers [77,78], 
among others [79–82].  Many studies have shown in both animal models and human 
studies that CTC count correlates with prognosis, suggesting that a higher CTC count 
is generally indicative of a worse survival rate and greater disease progression 
[51,61,63,83–88].  
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There is no single definitive approach for isolating or identifying CTCs from patient 
blood. The problem with isolating CTCs is their rareness in the blood, with CTC 
counts on the order of 1 per billion blood cells [89].  CTCs can be enriched by density 
centrifugation, which removes the majority of red blood cells, neutrophils, platelets, 
and plasma. However, the remaining leukocytes still greatly outnumber the CTCs; 
therefore, density centrifugation is usually used in conjunction with another isolation 
technique. Once CTCs are isolated, their identity must be confirmed. This is usually 
done by PCR or fluorescence microscopy [90]. A cell is considered a CTC if it meets 
the following criteria: a misshapen nucleus, positive for epithelial cell adhesion 
molecule (EpCAM) or cytokeratin (CK) expression, and negative for CD45, a 
leukocyte marker [91]. However, recent work has shown that CTCs are heterogeneous 
and one identification method may not work to identify all CTC subtypes [71,82]. 
Only one isolation technique, CellSearch, has been FDA-approved for the 
enumeration of patient CTC counts in prostate and breast cancer. CellSearch uses anti-
EpCAM antibody-coated magnetic beads to capture CTCs from blood samples and 
then a strong magnet is used to precipitate the aggregates out of solution. The cells 
attached to the beads are then stained for CK, CD45, and DAPI, a nuclear stain. 
Samples are processed through a specialized detector that detects and enumerates 
positively-identified, intact CTCs [90]. Other isolation techniques have been 
developed using similar approaches. For example, the Chalmers lab, among others, 
uses magnetic bead technology to isolate CTCs via negative-selection. In their 
process, magnetic beads are coated with anti-CD45 antibodies that capture 
contaminating leukocytes. This process allows for the identification of both EpCAM-
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positive and EpCAM-negative CTCs [51]. Nagrath et al. created a microfluidic “CTC-
chip” that applies anti-EpCAM antibodies to microfabricated posts. A blood sample is 
applied to the chip, where fluid flow produces collisions between the CTCs and the 
posts [92]. The same group extended this idea by designing a chip without posts but 
with a herringbone pattern etched onto a glass substrate. Anti-EpCAM antibody was 
then applied to the whole chip. This allows for a greater capture area, and the 
herringbone etching increases the turbidity of the flow, thereby increasing CTCs 
collisions with the chip surface [93].   
It is believed that CTCs facilitate metastasis by hijacking the process that leukocytes 
use when responding to inflammation signals. This involves the adhesion of cells to 
the vascular endothelium mediated by adhesion molecules such as E-selectin. Our 
group has employed this concept to develop a physiologic mimic microtube device 
that uses E-selectin adhesion to recruit CTCs to the surface and facilitate firm 
adhesion via antibody binding [81]. In the next section, the development and use of 
this technology is further detailed.  
 
1.2 CTC Capture by E-selectin 
E-selectin’s use as a capture agent started about a decade ago when the Liepmann lab 
developed a cell separation device that uses E-selectin to concentrate cell solutions. In 
this microfluidic device, microfabricated posts are coated in recombinant human E-
selectin (rhES) and cell solution is pumped through, allowing cells to be captured on 
the surface of each post. Two post geometries were tested: square pillars and slender, 
offset pillars. The offset pillars were shown to capture more cells initially, but the 
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square pillars enriched the cell solution better due to slower rolling speeds and less 
cell detachment. This device was not tested for CTC capture specifically, but in theory 
could be applied for that purpose [94]. In addition, Kim et al. developed a biomimetic 
chip to capture blood cells [95]. Rather than target one selectin interaction, they coated 
their chip with E-selectin, ICAM-1, and VCAM for the purpose of targeting all three 
selectins. However, they found that E-selectin was necessary for capture [95].  
CTCs from patients with prostate cancer were only recently shown to adhere to 
microtubes functionalized with rhES [96], but work to create a capture device using 
immobilized selectin started years earlier. Much of the work, in fact, was pioneered 
using a haematopoietic stem cell (HSPC) model. In this device, microrenathane tubes 
coated in P-selectin enriched HSPC samples seven-fold with an average purity of 
about 30% [97]. While this process represented a major advance, further work showed 
that by roughening the surface area of the tube with nanomaterials, one could greatly 
increase the efficiency of the device. For example, coating the tube with colloidal 
silica prior to protein absorption increased cell capture [98].  Capture was further 
increased with halloysite coatings; halloysite is naturally occurring aluminosilicate 
nanoparticles that range from 500-1200 nm in length and 40-200 nm in diameter. 
Combined hallyosite and P-selectin surfaces captured both KG1a and COLO205 cells 
at increased rates compared to tubes with P-selectin alone [99]. This technology was 
subsequently adapted for CTC isolation.  
To capture CTCs, a length of microrenathane (MRE) tubing is first coated with poly-
L-lysine to endow the tube with a positively charged surface that will facilitate the 
adsorption of the halloysite nanotubes. The halloysite coating is allowed to cure 
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overnight. Protein G is then added to the tube followed by a mixture of rhES and anti-
EpCAM antibody. Protein G binds to the Fc region of both the rhES and anti-EpCAM 
antibody allowing for consistent molecular orientation within the tube interior [100]. 
The technology was optimized and characterized using a leukemia cell line prior to 
testing with patient samples. This approach typically yields a capture efficiency of 
50% and CTC purities of >50% [81].  
Primary buffy coat samples were processed through tubes without halloysite (“smooth 
tubes”), halloysite-coated tubes, and using CellSearch. For each method, half a tube of 
blood (3.75 mL) was processed and the resulting normalized cell counts were 
calculated and compared (Figure 1.2). For nearly all cancer blood samples, both the 
smooth tubes and halloysite-coated tubes captured more cells than Cell Search. 
Halloysite-coated tubes show generally higher CTC purities than the smooth tubes, 
due to the inability of leukocytes to spread and firmly attach on halloysite [81].  
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Figure 1.2. Number of CTCs captured from the blood of cancer patients, along with 
the results of samples collected from healthy patients. Smooth tube device, halloysite-
coated device, and CellSearch methods were compared in parallel experiments, data 
from [81]. 
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1.3 Applications for E-selectin in Cancer Diagnosis and Treatment 
While CTC counts have primarily been used as a marker of disease progression, CTCs 
hold much potential for targeted, personalized therapy development. In fact, in the 
study that led to FDA-approval of CellSearch, CTC counts were correlated not just 
with disease progression, but also with response to treatment. Patients with >4 CTCs 
per sample were noted to have responded poorly to treatment [101]. Two other studies 
in prostate cancer also used CTCs count to track drug efficacy[102,103]. In the study 
by Reid et al., 63% of patients showed a CTC count decrease by half after treatment 
[102]. 
 
1.3.1 E-selectin capture for drug efficacy testing 
Our lab has exploited knowledge of E-selectin adhesion to cancer cells to explore the 
potential for a broadly applicable diagnostic test for the development of personalized 
treatment regimes. We hypothesized that by employing the same device as described 
in the previous section, one could use CTC samples to test for drug sensitivity prior to 
administration. CTCs represent an advantageous medium for drug testing because one 
CTC sample can contain multiple different subsets of cancer cells believed to reflect 
the heterogeneous nature of the primary tumor [104] and because of their 
demonstrated correlation with metastasis, which accounts for 90% of all cancer-related 
deaths [105]. 
In previous work, a simple procedure to test for drug efficacy using CTC count was 
created. Each blood sample was split into multiple aliquots, leaving one aliquot as an 
untreated reference control. Blood samples were treated with chemotherapeutic drugs 
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and incubated overnight.  The drug concentrations used in the study were chosen 
based on the peak plasma concentration determined by pharmacokinetic studies. After 
incubation, CTCs were isolated and enumerated. A reduction in CTC count, when 
compared to the reference control, was concluded to indicate drug sensitivity [106]. 
The method was first characterized using a cell line model that consisted of spiking a 
known number of prostate or breast cancer cells into the blood of a healthy donor. All 
of the cell lines tested were found to be sensitive to each drug in media and in blood, 
and the trend in cell count reduction followed the same pattern for both conditions.  
Following characterization, this method was tested on the blood from 7 cancer patients 
(3 breast, 2 prostate, 1 renal, 1 colon). Each patient’s response to the drugs varied, 
with 3 patients responding to both drugs, 3 were sensitive to one drug, and 1 showed 
no sensitivity. More detailed results of the primary sample experiments can be seen in 
Figure 1.3 [106]. 
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 Figure 1.3.  Patient samples were collected from three breast cancer patients (Br1, Br2, and Br3), 
two prostate cancer patients (Pr1 and Pr2), one renal and one colon cancer patient (Re1 and Co1, 
respectively). Each tube of whole blood was split into three aliquots and treated with vehicle control, 
20% peak plasma concentration (PPC), or 100% PPC of the appropriate drug. (Top) CTC counts of 
patient samples treated with chemotherapeutic drugs. (Bottom) Example micrographs of 2 patient 
samples. Blue- DAPI, Green- EpCAM, Red- CD45. Patients showed varied responses to the drugs 
as shown in the line graphs. Pr2 shows significant response to both drugs, which can be seen in the 
top set of fluorescent images as a reduction in the number of green cells in the treatment images 
compared the control. Re1 shows no sensitivity to docetaxel, but is sensitive doxorubicin, which is 
observed in the lower set of fluorescent images as no reduction in green cells and a reduction in the 
number of green cells, respectively. DT = docetaxel, DOX = doxorubicin, MTX = mitoxantrone. Error 
bars represent standard error of the mean. * P < 0.05, ** P < 0.01, *** P < 0.001; scale bar=50 um, 
from A.D. Hughes, J.R. Marshall, E. Keller, J.D. Powderly, B.T. Greene, M.R. King, Differential drug 
responses of circulating tumor cells within patient blood, Cancer Letters. (2013), [106]. Figure 
reprinted with permission. 
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There are several advantages to this system. First, it is a straightforward procedure that 
can be performed on standard laboratory equipment. Secondl, the method can be used 
with any CTC isolation device, for instance, CellSearch or CTC-Chip. Moreover, the 
technique supports the testing of intravenous drugs or combinations of therapeutics 
[106].  
 
1.3.2 E-selectin for Use in Targeted Cancer Therapy 
The fact that E-selectin can be used to recruit CTCs to surfaces suggests that it may 
also be useful in targeted therapeutics. Previous attempts have been made to create 
cancer drugs that exploit E-selectin adhesion including drugs targeting glycosylation, 
selectin ligands, but none of these formulations have reached the clinic [13,42]. Unlike 
previous technologies, we have explored the use of E-selectin as a targeting agent and 
employed a secondary protein, TNF-related apoptosis-inducing ligand (TRAIL) to 
induce apoptosis in CTCs [107]. TRAIL is a protein expressed by cells of the immune 
system, and the receptors for TRAIL, termed death receptors, have been shown to be 
upregulated on the surface of many types of cancer cells [108]. By employing the 
combination of TRAIL and E-selectin, this therapeutic increases its targeting of cancer 
cells and decreases its cytotoxicity toward healthy cells. 
Huang and King showed that selectin molecules have the ability to target cells by 
using P-selectin-coated liposomes to deliver siRNA to HL60 cells. Liposomes were 
absorbed onto the surface of MRE tubes and HL60 cells rolled across the surface, and 
the encapsulated siRNA was successfully delivered to the cells to induce a knockdown 
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of the elastase gene (ELA2) to less than half of the original expression level [109]. E-
selectin has also served as a successful targeting protein for liposomes. Rh-ES was 
conjugated to the surface of liposomes encapsulating doxorubicin and used to treat 
cancer cells in vitro. E-selectin was successful in targeting cancer cells as shown by 
liposomes adhering to nearly 100% of cells. Under static conditions, the targeted 
liposomes experienced a similar kill rate to normal liposomal doxorubicin, but killed 
fewer cells than soluble doxorubicin. To study the effect of shear on the targeting and 
killing of cancer cells by E-selectin functionalized liposomes, they were adsorbed onto 
the surface of MRE tubes and cells were perfused through the tubes. Under dynamic 
conditions, E-selectin functionalized liposomes killed significantly more cells than 
identical liposomes containing no doxorubicin, although the kill rate was less than that 
of soluble doxorubicin. When a halloysite coating was added to the MRE tubing 
before liposome adsorption, however, the number of apoptotic cells increased greatly 
and the observed difference in the kill rates of the functionalized liposomes and 
soluble doxorubicin was lower [110]. 
In a study by Rana et al. the dual power of TRAIL and E-selectin was observed. MRE 
tubing was coated with a combination of rhES and TRAIL and COLO205 cells were 
flowed through the device for 1-2 hours. While 1 hour of flow did not produce 
significant apoptosis, after 2 hours less than 40% of COLO-205 cells remained viable. 
Pretreatment with 1 mM aspirin significantly increased the effectiveness of the 
surface, bringing the kill rate of 1-hour of rolling to that of the 2-hour treatment 
without aspirin[111].  
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The work culminated in the development of E-selectin/TRAIL-functionalized 
liposomes that target CTCs within the bloodstream. Dual-functionalized liposomes 
were shown to kill significantly more cancer cells than naked liposomes, E-selectin 
only liposomes, or TRAIL only liposomes. The liposomes also bound to human 
leukocytes in vitro without causing apoptosis. The cancer cell killing effect was 
greatly enhanced when cells were in the whole blood environment, with less than 5% 
of cells remaining viable. It was shown in this study that the liposomes are capable of 
not only killing cancer cells directly, but more importantly also attach to leukocytes 
and remain available to bind to cancer cells and induce death. This dual action 
enhances the utility of the therapy by increasing the circulation time of the therapy. 
One limitation of previous TRAIL therapies has been its short circulation time (15-30 
minutes) and rapid clearance. Interestingly, E-selectin liposomes without therapeutic 
were found to cause CTCs to be retained in the circulation in vivo rather than adhering 
to the vascular endothelium by competitive inhibition. This was shown in a mouse 
model where COLO205 cells were injected via the tail vein, followed by liposome 
therapy, control liposomes, buffer, or soluble TRAIL. The CTCs were collected via 
cardiac puncture and enumerated after 2-3 hours in culture. Mice treated with E-
selectin/TRAIL liposomes had the fewest remaining CTCs after treatment (Figure 
1.4). In addition, the ES/TRAIL liposome treatment decreased the number of cells that 
lodged in the lungs of the mice. This study shows the importance and potential for E-
selectin as a CTC targeting molecule [107].  
 
  18 
 
Figure 1.4. E-selectin/TRAIL liposomes eliminate CTC in vivo. A) Schematic of 
procedure for in vivo liposome experiments. B) Flow cytometry of COLO205 cells in 
vitro (L), recovered from cardiac puncture of ES-liposome treated mice (C), 
recovered from ES/TRAIL-liposome treated mice (R). SSL: side-scattered light; FSC: 
forward-scattered light. C) Number of viable cells recovered from blood of mice 
compared by treatments. n=3 for all samples. Bars represent the mean ± SD in each 
treatment group. *P < 0.01, **P < 0.001, ***P < 0.0001 (one-way ANOVA with Tukey 
posttest). D) Representative micrographs of cells recovered from mouse blood. Scale 
bar = 20 µm. E) Leukocytes functionalized with fluorescent ES/TRAIL liposomes 
recovered during cardiac puncture.  Scale bar = 50 µm. ES/TRAIL liposomes bound 
to leukocytes in the circulation of mice and successfully killed COLO205 cells in the 
circulation of mice, from M.J. Mitchell, E. Wayne, K. Rana, C.B. Schaffer, M.R. King, 
TRAIL-coated leukocytes that kill cancer cells in the circulation., Proceedings of the 
National Academy of Sciences of the United States of America. 111 (2014) 930–5, 
[107]. Figure reprinted with permission. 
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1.4 Conclusions  
Ever since the selectin family of adhesion molecules was discovered in the late 1980s, 
research has looked at the importance of this molecule in immune and cancer 
interactions. Recent work has revealed new ways that E-selectin adhesion can be used 
to detect and kill CTCs (Figure 1.5). It has been demonstrated that E-selectin, in 
combination with other specific cancer antibodies, can be used to capture CTCs from 
the blood of patients to better characterize a patient’s prognosis and also to potentially 
test living tumor cells for the most effective treatment option. Going further, E-
selectin has been used as a targeting molecule for cancer treatment. By combining the 
targeting of E-selectin with the killing and targeting of TRAIL, CTCs in mice were 
killed in the bloodstream and the number of embedded cells in the lungs was 
decreased significantly. E-selectin has great potential in the realm of cancer treatment 
and its full utility is just now being fully appreciated. 
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Figure 1.5. Functions and uses for E-selectin in cancer treatment. 
E-selectin
Cancer Cell 
 Metastasis
Leukocyte Recruitment
       to Inflammation
Targeting Cancer Cells
Targeting Leukocytes
Capturing CTC Testing Drug 
    Efficacy
In Vitro Applications
In Vivo ApplicationsN
or
m
al
 F
un
ct
io
ns
  21 
REFERENCES 
 
[1] M.H. Siegelman, M. van de Rijn, I.L. Weissman, Mouse lymph node homing 
receptor cDNA clone encodes a glycoprotein revealing tandem interaction 
domains., Science (New York, N.Y.). 243 (1989) 1165–72. 
[2] L.A. Lasky, M.S. Singer, T.A. Yednock, D. Dowbenko, C. Fennie, H. 
Rodriguez, et al., Cloning of a lymphocyte homing receptor reveals a lectin 
domain., Cell. 56 (1989) 1045–55. 
[3] G.I. Johnston, R.G. Cook, R.P. McEver, Cloning of GMP-140, a granule 
membrane protein of platelets and endothelium: sequence similarity to proteins 
involved in cell adhesion and inflammation., Cell. 56 (1989) 1033–44. 
[4] M.P. Bevilacqua, S. Stengelin, M.A. Gimbrone, B. Seed, Endothelial leukocyte 
adhesion molecule 1: an inducible receptor for neutrophils related to 
complement regulatory proteins and lectins., Science (New York, N.Y.). 243 
(1989) 1160–5. 
[5] M.L. Watson, S.F. Kingsmore, G.I. Johnston, M.H. Siegelman, M.M. Le Beau, 
R.S. Lemons, et al., Genomic organization of the selectin family of leukocyte 
adhesion molecules on human and mouse chromosome 1., The Journal of 
Experimental Medicine. 172 (1990) 263–72. 
[6] M.P. Bevilacqua, R.M. Nelson, Selectins., The Journal of Clinical 
Investigation. 91 (1993) 379–87. 
[7] V.J. Toothill, J. a Van Mourik, H.K. Niewenhuis, M.J. Metzelaar, J.D. Pearson, 
Characterization of the enhanced adhesion of neutrophil leukocytes to 
thrombin-stimulated endothelial cells., Journal of Immunology (Baltimore, 
Md.!: 1950). 145 (1990) 283–91. 
[8] M.B. Lawrence, T.A. Springer, Leukocytes roll on a selectin at physiologic 
flow rates: distinction from and prerequisite for adhesion through integrins., 
Cell. 65 (1991) 859–73. 
[9] D. Vestweber, J.E. Blanks, Mechanisms that regulate the function of the 
selectins and their ligands., Physiological Reviews. 79 (1999) 181–213. 
[10] Y. Geng, J.R. Marshall, M.R. King, Glycomechanics of the metastatic cascade: 
tumor cell-endothelial cell interactions in the circulation., Annals of Biomedical 
Engineering. 40 (2012) 790–805. 
  22 
[11] S.R. Barthel, J.D. Gavino, L. Descheny, C.J. Dimitroff, Targeting selectins and 
selectin ligands in inflammation and cancer., Expert Opinion on Therapeutic 
Targets. 11 (2007) 1473–91. 
[12] P.R. Crocker, T. Feizi, Carbohydrate recognition systems: functional triads in 
cell-cell interactions., Current Opinion in Structural Biology. 6 (1996) 679–91. 
[13] H. Läubli, L. Borsig, Selectins promote tumor metastasis., Seminars in Cancer 
Biology. 20 (2010) 169–77. 
[14] K.L. Moore, Structure and function of P-selectin glycoprotein ligand-1., 
Leukemia & Lymphoma. 29 (1998) 1–15. 
[15] D. Lauri, L. Needham, I. Martin-Padura, E. Dejana, Tumor cell adhesion to 
endothelial cells: endothelial leukocyte adhesion molecule-1 as an inducible 
adhesive receptor specific for colon carcinoma cells., Journal of the National 
Cancer Institute. 83 (1991) 1321–4. 
[16] G.E. Rice, M.P. Bevilacqua, An inducible endothelial cell surface glycoprotein 
mediates melanoma adhesion., Science (New York, N.Y.). 246 (1989) 1303–6. 
[17] G. Mannori, P. Crottet, O. Cecconi, K. Hanasaki, A. Aruffo, R.M. Nelson, et 
al., Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of 
mucin-type glycoproteins., Cancer Research. 55 (1995) 4425–31. 
[18] M.M. Burdick, J.M. McCaffery, Y.S. Kim, B.S. Bochner, K. Konstantopoulos, 
Colon carcinoma cell glycolipids, integrins, and other glycoproteins mediate 
adhesion to HUVECs under flow., American Journal of Physiology. Cell 
Physiology. 284 (2003) C977–87. 
[19] P.-L. Tremblay, F.A. Auger, J. Huot, Regulation of transendothelial migration 
of colon cancer cells by E-selectin-mediated activation of p38 and ERK MAP 
kinases., Oncogene. 25 (2006) 6563–73. 
[20] J. Laferrière, F. Houle, J. Huot, Adhesion of HT-29 colon carcinoma cells to 
endothelial cells requires sequential events involving E-selectin and integrin 
beta4., Clinical & Experimental Metastasis. 21 (2004) 257–64. 
[21] R. Sawada, S. Tsuboi, M. Fukuda, Differential E-selectin-dependent adhesion 
efficiency in sublines of a human colon cancer exhibiting distinct metastatic 
potentials., The Journal of Biological Chemistry. 269 (1994) 1425–31. 
[22] C.J. Dimitroff, M. Lechpammer, D. Long-Woodward, J.L. Kutok, Rolling of 
human bone-metastatic prostate tumor cells on human bone marrow 
  23 
endothelium under shear flow is mediated by E-selectin., Cancer Research. 64 
(2004) 5261–9. 
[23] S.R. Barthel, G.K. Wiese, J. Cho, M.J. Opperman, D.L. Hays, J. Siddiqui, et al., 
Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell 
trafficking., Proceedings of the National Academy of Sciences of the United 
States of America. 106 (2009) 19491–6. 
[24] J. Li, A.D. Guillebon, J. Hsu, S.R. Barthel, C.J. Dimitroff, Y.-F. Lee, et al., 
Human fucosyltransferase 6 enables prostate cancer metastasis to bone., British 
Journal of Cancer. 109 (2013) 3014–22. 
[25] T. Narita, N. Kawasaki-Kimura, N. Matsuura, H. Funahashi, R. Kannagi, 
Adhesion of Human Breast Cancer Cells to Vascular Endothelium Mediated by 
Sialyl Lewis &supx; /E-selectin., Breast Cancer (Tokyo, Japan). 3 (1996) 19–
23. 
[26] A. Tözeren, H.K. Kleinman, D.S. Grant, D. Morales, A.M. Mercurio, S.W. 
Byers, E-selectin-mediated dynamic interactions of breast- and colon-cancer 
cells with endothelial-cell monolayers., International Journal of Cancer. Journal 
International Du Cancer. 60 (1995) 426–31. 
[27] V.S. Shirure, K.A. Henson, R.L. Schnaar, L. Nimrichter, M.M. Burdick, 
Gangliosides expressed on breast cancer cells are E-selectin ligands., 
Biochemical and Biophysical Research Communications. 406 (2011) 423–9. 
[28] V.S. Shirure, N.M. Reynolds, M.M. Burdick, Mac-2 binding protein is a novel 
E-selectin ligand expressed by breast cancer cells., PloS One. 7 (2012) e44529. 
[29] S. Chandrasekaran, Y. Geng, L.A. DeLouise, M.R. King, Effect of homotypic 
and heterotypic interaction in 3D on the E-selectin mediated adhesive properties 
of breast cancer cell lines., Biomaterials. 33 (2012) 9037–48. 
[30] Y. Geng, K. Yeh, T. Takatani, M.R. King, Three to Tango: MUC1 as a Ligand 
for Both E-Selectin and ICAM-1 in the Breast Cancer Metastatic Cascade., 
Frontiers in Oncology. 2 (2012) 76. 
[31] U. Richter, C. Schröder, D. Wicklein, T. Lange, S. Geleff, V. Dippel, et al., 
Adhesion of small cell lung cancer cells to E- and P-selectin under 
physiological flow conditions: implications for metastasis formation., 
Histochemistry and Cell Biology. 135 (2011) 499–512. 
[32] M. ten Kate, L.J. Hofland, P.M. van Koetsveld, J. Jeekel, C.H.J. van Eijck, Pro-
inflammatory cytokines affect pancreatic carcinoma cell. Endothelial cell 
interactions., JOP!: Journal of the Pancreas. 7 (2006) 454–64. 
  24 
[33] F. Nozawa, M. Hirota, A. Okabe, M. Shibata, T. Iwamura, Y. Haga, et al., 
Tumor necrosis factor alpha acts on cultured human vascular endothelial cells 
to increase the adhesion of pancreatic cancer cells., Pancreas. 21 (2000) 392–8. 
[34] M. Takada, M. Yamamoto, Y. Hasegawa, Y. Saitoh, Endothelial leukocyte 
adhesion molecule-1-mediated vasoinvasion of human pancreatic 
adenocarcinoma., The Journal of Surgical Research. 59 (1995) 653–7. 
[35] K. Iwai, H. Ishikura, M. Kaji, H. Sugiura, A. Ishizu, C. Takahashi, et al., 
Importance of E-selectin (ELAM-1) and sialyl Lewis(a) in the adhesion of 
pancreatic carcinoma cells to activated endothelium., International Journal of 
Cancer. Journal International Du Cancer. 54 (1993) 972–7. 
[36] K. Numahata, M. Satoh, K. Handa, S. Saito, C. Ohyama, A. Ito, et al., Sialosyl-
Le(x) expression defines invasive and metastatic properties of bladder 
carcinoma., Cancer. 94 (2002) 673–85. 
[37] S.D. Hoff, Y. Matsushita, D.M. Ota, K.R. Cleary, T. Yamori, S. Hakomori, et 
al., Increased expression of sialyl-dimeric LeX antigen in liver metastases of 
human colorectal carcinoma., Cancer Research. 49 (1989) 6883–8. 
[38] S. Nakamori, M. Kameyama, S. Imaoka, H. Furukawa, O. Ishikawa, Y. Sasaki, 
et al., Increased expression of sialyl Lewisx antigen correlates with poor 
survival in patients with colorectal carcinoma: clinicopathological and 
immunohistochemical study., Cancer Research. 53 (1993) 3632–7. 
[39] T. Nakayama, M. Watanabe, T. Katsumata, T. Teramoto, M. Kitajima, 
Expression of sialyl Lewis(a) as a new prognostic factor for patients with 
advanced colorectal carcinoma., Cancer. 75 (1995) 2051–6. 
[40] R. Kannagi, M. Izawa, T. Koike, K. Miyazaki, N. Kimura, Carbohydrate-
mediated cell adhesion in cancer metastasis and angiogenesis., Cancer Science. 
95 (2004) 377–84. 
[41] L. Terraneo, L. Avagliano, A. Caretti, P. Bianciardi, D. Tosi, G. Pietro 
Bulfamante, et al., Expression of carbohydrate-antigen sialyl-Lewis a on colon 
cancer cells promotes xenograft growth and angiogenesis in nude mice., The 
International Journal of Biochemistry & Cell Biology. 45 (2013) 2796–800. 
[42] S. Hakomori, Tumor malignancy defined by aberrant glycosylation and 
sphingo(glyco)lipid metabolism., Cancer Research. 56 (1996) 5309–18. 
[43] K. Handa, T. White, K. Ito, H. Fang, S. Wang, S. Hakomori, P-selectin-
dependent adhesion of human cancer-cells - requirement for coexpression of a 
  25 
psgl-1-like core protein and the glycosylation process for sialosyl-le(x) or 
sialosyl-le(a)., International Journal of Oncology. 6 (1995) 773–81. 
[44] A. Takada, K. Ohmori, T. Yoneda, K. Tsuyuoka, A. Hasegawa, M. Kiso, et al., 
Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to 
adhesion of human cancer cells to vascular endothelium., Cancer Research. 53 
(1993) 354–61. 
[45] W.D. Hanley, M.M. Burdick, K. Konstantopoulos, R. Sackstein, CD44 on 
LS174T colon carcinoma cells possesses E-selectin ligand activity., Cancer 
Research. 65 (2005) 5812–7. 
[46] S. Hakomori, Novel endothelial cell activation factor(s) released from activated 
platelets which induce E-selectin expression and tumor cell adhesion to 
endothelial cells: a preliminary note., Biochemical and Biophysical Research 
Communications. 203 (1994) 1605–13. 
[47] D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation., Cell. 
144 (2011) 646–74. 
[48] D.A. Sipkins, X. Wei, J.W. Wu, J.M. Runnels, D. Côté, T.K. Means, et al., In 
vivo imaging of specialized bone marrow endothelial microdomains for tumour 
engraftment., Nature. 435 (2005) 969–73. 
[49] T.R. Ashworth, A case of cancer in which cells similar to those in the tumors 
were seen in the blood after death., Aus Med J. 14 (1869) 146–149. 
[50] A.J. Armstrong, M.S. Marengo, S. Oltean, G. Kemeny, R.L. Bitting, J.D. 
Turnbull, et al., Circulating tumor cells from patients with advanced prostate 
and breast cancer display both epithelial and mesenchymal markers., Molecular 
Cancer Research!: MCR. 9 (2011) 997–1007. 
[51] P. Balasubramanian, J.C. Lang, K.R. Jatana, B. Miller, E. Ozer, M. Old, et al., 
Multiparameter analysis, including EMT markers, on negatively enriched blood 
samples from patients with squamous cell carcinoma of the head and neck., 
PloS One. 7 (2012) e42048. 
[52] C.-L. Chen, D. Mahalingam, P. Osmulski, R.R. Jadhav, C.-M. Wang, R.J. 
Leach, et al., Single-cell analysis of circulating tumor cells identifies 
cumulative expression patterns of EMT-related genes in metastatic prostate 
cancer., The Prostate. (2012). 
[53] G. Kallergi, M. a Papadaki, E. Politaki, D. Mavroudis, V. Georgoulias, S. 
Agelaki, Epithelial to mesenchymal transition markers expressed in circulating 
  26 
tumour cells of early and metastatic breast cancer patients., Breast Cancer 
Research!: BCR. 13 (2011) R59. 
[54] A.D. Rhim, E.T. Mirek, N.M. Aiello, A. Maitra, J.M. Bailey, F. McAllister, et 
al., EMT and Dissemination Precede Pancreatic Tumor Formation, Cell. 148 
(2012) 349–361. 
[55] M. Yu, A. Bardia, B.S. Wittner, S.L. Stott, M.E. Smas, D.T. Ting, et al., 
Circulating breast tumor cells exhibit dynamic changes in epithelial and 
mesenchymal composition., Science (New York, N.Y.). 339 (2013) 580–4. 
[56] L. Zhang, L.D. Ridgway, M.D. Wetzel, J. Ngo, W. Yin, D. Kumar, et al., The 
Identification and Characterization of Breast Cancer CTCs Competent for Brain 
Metastasis, Science Translational Medicine. 5 (2013) 180ra48–180ra48. 
[57] C.-Y. Lu, H.-L. Tsai, Y.-H. Uen, H.-M. Hu, C.-W. Chen, T.-L. Cheng, et al., 
Circulating tumor cells as a surrogate marker for determining clinical outcome 
to mFOLFOX chemotherapy in patients with stage III colon cancer., British 
Journal of Cancer. (2013) 791–797. 
[58] A. Markiewicz, M. Książkiewicz, M. Wełnicka-Jaśkiewicz, B. Seroczyńska, J. 
Skokowski, J. Szade, et al., Mesenchymal Phenotype of CTC-Enriched Blood 
Fraction and Lymph Node Metastasis Formation Potential., PloS One. 9 (2014) 
e93901. 
[59] E. Rossi, M. Fassan, M. Aieta, F. Zilio, R. Celadin, M. Borin, et al., Dynamic 
changes of live/apoptotic circulating tumour cells as predictive marker of 
response to sunitinib in metastatic renal cancer., British Journal of Cancer. 107 
(2012) 1286–94. 
[60] B. Aktas, V. Müller, M. Tewes, J. Zeitz, S. Kasimir-Bauer, C.R. Loehberg, et 
al., Comparison of estrogen and progesterone receptor status of circulating 
tumor cells and the primary tumor in metastatic breast cancer patients., 
Gynecologic Oncology. 122 (2011) 356–60. 
[61] F.-C. Bidard, D. Hajage, T. Bachelot, S. Delaloge, E. Brain, M. Campone, et 
al., Assessment of circulating tumor cells and serum markers for progression-
free survival prediction in metastatic breast cancer: a prospective observational 
study., Breast Cancer Research!: BCR. 14 (2012) R29. 
[62] T. Fehm, O. Hoffmann, B. Aktas, S. Becker, E.F. Solomayer, D. Wallwiener, et 
al., Detection and characterization of circulating tumor cells in blood of primary 
breast cancer patients by RT-PCR and comparison to status of bone marrow 
disseminated cells., Breast Cancer Research!: BCR. 11 (2009) R59. 
  27 
[63] T.L. Green, J.M. Cruse, R.E. Lewis, Circulating tumor cells (CTCs) from 
metastatic breast cancer patients linked to decreased immune function and 
response to treatment., Experimental and Molecular Pathology. (2013). 
[64] H.J. Lee, J.H. Oh, J.M. Oh, J.-M. Park, J.-G. Lee, M.S. Kim, et al., Efficient 
Isolation and Accurate In Situ Analysis of Circulating Tumor Cells Using 
Detachable Beads and a High-Pore-Density Filter, Angewandte Chemie 
International Edition. (2013) n/a–n/a. 
[65] B.A.S. Jaeger, J. Jueckstock, U. Andergassen, J. Salmen, F. Schochter, V. Fink, 
et al., Evaluation of two different analytical methods for circulating tumor cell 
detection in peripheral blood of patients with primary breast cancer., BioMed 
Research International. 2014 (2014) 491459. 
[66] S. Igawa, K. Gohda, T. Fukui, S. Ryuge, S. Otani, A. Masago, et al., Circulating 
tumor cells as a prognostic factor in patients with small cell lung cancer., 
Oncology Letters. 7 (2014) 1469–1473. 
[67] F.I. Thege, T.B. Lannin, T.N. Saha, S. Tsai, M.L. Kochman, M.A. 
Hollingsworth, et al., Microfluidic immunocapture of circulating pancreatic 
cells using parallel EpCAM and MUC1 capture: characterization, optimization 
and downstream analysis., Lab on a Chip. 14 (2014) 1775–84. 
[68] M.J.M. Magbanua, E. V Sosa, J.H. Scott, J. Simko, C. Collins, D. Pinkel, et al., 
Isolation and genomic analysis of circulating tumor cells from castration 
resistant metastatic prostate cancer., BMC Cancer. 12 (2012) 78. 
[69] J.P. Gleghorn, E.D. Pratt, D. Denning, H. Liu, N.H. Bander, S.T. Tagawa, et al., 
Capture of circulating tumor cells from whole blood of prostate cancer patients 
using geometrically enhanced differential immunocapture (GEDI) and a 
prostate-specific antibody., Lab on a Chip. 10 (2010) 27–9. 
[70] J. Barbazán, L. Alonso-Alconada, L. Muinelo-Romay, M. Vieito, A. Abalo, M. 
Alonso-Nocelo, et al., Molecular characterization of circulating tumor cells in 
human metastatic colorectal cancer., PloS One. 7 (2012) e40476. 
[71] E. Denève, S. Riethdorf, J. Ramos, D. Nocca, A. Coffy, J.-P. Daurès, et al., 
Capture of Viable Circulating Tumor Cells in the Liver of Colorectal Cancer 
Patients., Clinical Chemistry. 000 (2013) 1–9. 
[72] H. Iinuma, K. Okinaga, M. Adachi, K. Suda, T. Sekine, K. Sakagawa, et al., 
Detection of tumor cells in blood using CD45 magnetic cell separation followed 
by nested mutant allele-specific amplification of p53 and K-ras genes in 
patients with colorectal cancer., International Journal of Cancer. Journal 
International Du Cancer. 89 (2000) 337–44. 
  28 
[73] A. Gradilone, R. Iacovelli, E. Cortesi, C. Raimondi, W. Gianni, C. Nicolazzo, et 
al., Circulating tumor cells and “suspicious objects” evaluated through 
CellSearch® in metastatic renal cell carcinoma., Anticancer Research. 31 
(2011) 4219–21. 
[74] J.M. McKiernan, R. Buttyan, N.H. Bander, A. de la Taille, M.D. Stifelman, 
E.R. Emanuel, et al., The detection of renal carcinoma cells in the peripheral 
blood with an enhanced reverse transcriptase-polymerase chain reaction assay 
for MN/CA9., Cancer. 86 (1999) 492–7. 
[75] S. Wang, G. Zheng, B. Cheng, F. Chen, Z. Wang, Y. Chen, et al., Circulating 
Tumor Cells (CTCs) Detected by RT-PCR and Its Prognostic Role in Gastric 
Cancer: A Meta-Analysis of Published Literature., PloS One. 9 (2014) e99259. 
[76] A. Pituch-Noworolska, J. Wieckiewicz, A. Krzeszowiak, J. Stachura, I. 
Ruggiero, M. Gawlicka, et al., Evaluation of circulating tumour cells expressing 
CD44 variants in the blood of gastric cancer patients by flow cytometry., 
Anticancer Research. 18 (n.d.) 3747–52. 
[77] P. Gazzaniga, A. Gradilone, E. de Berardinis, G.M. Busetto, C. Raimondi, O. 
Gandini, et al., Prognostic value of circulating tumor cells in nonmuscle 
invasive bladder cancer: a CellSearch analysis., Annals of Oncology!: Official 
Journal of the European Society for Medical Oncology / ESMO. 23 (2012) 
2352–6. 
[78] T. Okegawa, K. Hayashi, H. Hara, K. Nutahara, E. Higashihara, 
Immunomagnetic quantification of circulating tumor cells in patients with 
urothelial cancer., International Journal of Urology!: Official Journal of the 
Japanese Urological Association. 17 (2010) 254–8. 
[79] P. Joshi, B. Jacobs, A. Derakhshan, L.R. Moore, P. Elson, P.L. Triozzi, et al., 
Enrichment of circulating melanoma cells (CMCs) using negative selection 
from patients with metastatic melanoma., Oncotarget. 5 (2014) 2450–61. 
[80] C.G. Rao, D. Chianese, G. V Doyle, M.C. Miller, T. Russell, R. a Sanders, et 
al., Expression of epithelial cell adhesion molecule in carcinoma cells present in 
blood and primary and metastatic tumors., International Journal of Oncology. 
27 (2005) 49–57. 
[81] A.D. Hughes, J. Mattison, L.T. Western, J.D. Powderly, B.T. Greene, M.R. 
King, Microtube device for selectin-mediated capture of viable circulating 
tumor cells from blood., Clinical Chemistry. 58 (2012) 846–53. 
  29 
[82] P.K. Grover, A.G. Cummins, T.J. Price, J.E. Hardingham, Circulating tumour 
cells!: the evolving concept and the inadequacy of their enrichment by EpCAM-
based methodology for basic and clinical cancer research, (2014) 1–11. 
[83] I. Baccelli, A. Schneeweiss, S. Riethdorf, A. Stenzinger, A. Schillert, V. Vogel, 
et al., Identification of a population of blood circulating tumor cells from breast 
cancer patients that initiates metastasis in a xenograft assay., Nature 
Biotechnology. (2013). 
[84] Z.C. Fan, J. Yan, G. Da Liu, X.Y. Tan, X.F. Weng, W.Z. Wu, et al., In vivo 
flow cytometry visualizes the effects of tumor resection on metastasis by real-
time monitoring of rare circulating cancer cells., Cancer Research. (2012). 
[85] J.B. Smerage, G.T. Budd, G. V Doyle, M. Brown, C. Paoletti, M. Muniz, et al., 
Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with 
metastatic breast cancer., Molecular Oncology. 7 (2013) 680–92. 
[86] Y.-F. Sun, Y. Xu, X.-R. Yang, W. Guo, X. Zhang, S.-J. Qiu, et al., Circulating 
stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate 
poor prognosis of hepatocellular carcinoma after curative resection., 
Hepatology (Baltimore, Md.). 57 (2013) 1458–68. 
[87]  et al Tateaki Naito, MD, PhD,* Fumihiro Tanaka, MD, PhD,† Akira Ono, MD, 
Prognostic Impact of Circulating Tumor Cells in Patients, Journal of Thoracic 
Oncology. (2012) 1–8. 
[88] L. Zhao, P. Li, F. Li, Y. Yang, N. Liu, L. Cai, The prognostic value of 
circulating tumor cells lacking cytokeratins in metastatic breast cancer patients., 
Journal of Cancer Research and Therapeutics. 9 (2013) 29–37. 
[89] A.D. Hughes, M.R. King, Nanobiotechnology for the capture and manipulation 
of circulating tumor cells., Wiley Interdisciplinary Reviews. Nanomedicine and 
Nanobiotechnology. 4 (n.d.) 291–309. 
[90] E. Diamond, G.Y. Lee, N.H. Akhtar, B.J. Kirby, P. Giannakakou, S.T. Tagawa, 
et al., Isolation and characterization of circulating tumor cells in prostate 
cancer., Frontiers in Oncology. 2 (2012) 131. 
[91] W.J. Allard, J. Matera, M.C. Miller, M. Repollet, M.C. Connelly, C. Rao, et al., 
Tumor cells circulate in the peripheral blood of all major carcinomas but not in 
healthy subjects or patients with nonmalignant diseases., Clinical Cancer 
Research!: an Official Journal of the American Association for Cancer 
Research. 10 (2004) 6897–904. 
  30 
[92] S. Nagrath, L. V Sequist, S. Maheswaran, D.W. Bell, D. Irimia, L. Ulkus, et al., 
Isolation of rare circulating tumour cells in cancer patients by microchip 
technology., Nature. 450 (2007) 1235–9. 
[93] S.L. Stott, C.-H. Hsu, D.I. Tsukrov, M. Yu, D.T. Miyamoto, B.A. Waltman, et 
al., Isolation of circulating tumor cells using a microvortex-generating 
herringbone-chip., Proceedings of the National Academy of Sciences of the 
United States of America. 107 (2010) 18392–7. 
[94] W.C. Chang, L.P. Lee, D. Liepmann, Biomimetic technique for adhesion-based 
collection and separation of cells in a microfluidic channel., Lab on a Chip. 5 
(2005) 64–73. 
[95] S.K. Kim, W.K. Moon, J.Y. Park, H. Jung, Inflammatory mimetic microfluidic 
chip by immobilization of cell adhesion molecules for T cell adhesion., The 
Analyst. 137 (2012) 4062–8. 
[96] G. Gakhar, V.N. Navarro, M. Jurish, G.Y. Lee, S.T. Tagawa, N.H. Akhtar, et 
al., Circulating tumor cells from prostate cancer patients interact with E-selectin 
under physiologic blood flow., PloS One. 8 (2013) e85143. 
[97] J.C. Wojciechowski, S.D. Narasipura, N. Charles, D. Mickelsen, K. Rana, M.L. 
Blair, et al., Capture and enrichment of CD34-positive haematopoietic stem and 
progenitor cells from blood circulation using P-selectin in an implantable 
device., British Journal of Haematology. 140 (2008) 673–81. 
[98] W. Han, B.A. Allio, D.G. Foster, M.R. King, Nanoparticle coatings for 
enhanced capture of flowing cells in microtubes., ACS Nano. 4 (2010) 174–80. 
[99] A.D. Hughes, M.R. King, Use of naturally occurring halloysite nanotubes for 
enhanced capture of flowing cells., Langmuir!: the ACS Journal of Surfaces and 
Colloids. 26 (2010) 12155–64. 
[100] A.D. Hughes, J. Mattison, J.D. Powderly, B.T. Greene, M.R. King, Rapid 
isolation of viable circulating tumor cells from patient blood samples., Journal 
of Visualized Experiments!: JoVE. (2012) e4248. 
[101] H.I. Scher, X. Jia, J.S. de Bono, M. Fleisher, K.J. Pienta, D. Raghavan, et al., 
Circulating tumour cells as prognostic markers in progressive, castration-
resistant prostate cancer: a reanalysis of IMMC38 trial data., The Lancet 
Oncology. 10 (2009) 233–9. 
[102] A.H.M. Reid, G. Attard, D.C. Danila, N.B. Oommen, D. Olmos, P.C. Fong, et 
al., Significant and sustained antitumor activity in post-docetaxel, castration-
resistant prostate cancer with the CYP17 inhibitor abiraterone acetate., Journal 
  31 
of Clinical Oncology!: Official Journal of the American Society of Clinical 
Oncology. 28 (2010) 1489–95. 
[103] D.C. Danila, M.J. Morris, J.S. de Bono, C.J. Ryan, S.R. Denmeade, M.R. 
Smith, et al., Phase II multicenter study of abiraterone acetate plus prednisone 
therapy in patients with docetaxel-treated castration-resistant prostate cancer., 
Journal of Clinical Oncology!: Official Journal of the American Society of 
Clinical Oncology. 28 (2010) 1496–501. 
[104] F. Davnall, C.S.P. Yip, G. Ljungqvist, M. Selmi, F. Ng, B. Sanghera, et al., 
Assessment of tumor heterogeneity: an emerging imaging tool for clinical 
practice?, Insights into Imaging. 3 (2012) 573–89. 
[105] D.B. Longley, P.G. Johnston, Molecular mechanisms of drug resistance., The 
Journal of Pathology. 205 (2005) 275–92. 
[106] A.D. Hughes, J.R. Marshall, E. Keller, J.D. Powderly, B.T. Greene, M.R. King, 
Differential drug responses of circulating tumor cells within patient blood, 
Cancer Letters. (2013). 
[107] M.J. Mitchell, E. Wayne, K. Rana, C.B. Schaffer, M.R. King, TRAIL-coated 
leukocytes that kill cancer cells in the circulation., Proceedings of the National 
Academy of Sciences of the United States of America. 111 (2014) 930–5. 
[108] M. Kim, D. Seol, P. D, Chapter 7: Death Signaling and Therapeutic 
Applications of TRAIL, Aids. 2 (n.d.) 133–148. 
[109] Z. Huang, M.R. King, An immobilized nanoparticle-based platform for efficient 
gene knockdown of targeted cells in the circulation., Gene Therapy. 16 (2009) 
1271–82. 
[110] M.J. Mitchell, C.S. Chen, V. Ponmudi, A.D. Hughes, M.R. King, E-selectin 
liposomal and nanotube-targeted delivery of doxorubicin to circulating tumor 
cells., Journal of Controlled Release!: Official Journal of the Controlled Release 
Society. 160 (2012) 609–17. 
[111] K. Rana, C.A. Reinhart-King, M.R. King, Inducing apoptosis in rolling cancer 
cells: a combined therapy with aspirin and immobilized TRAIL and E-selectin., 
Molecular Pharmaceutics. 9 (2012) 2219–27.  
 
  32 
 
Chapter 2 
 
Patient-Specific Drug Efficacy Analysis on Circulating Tumor 
Cells Captured from Peripheral Blood 
 
Portions of this chapter were adapted from: 
A.D. Hughes, J.R. Marshall, E. Keller, J.D. Powderly, B.T. Greene, M.R. King, 
Differential drug responses of circulating tumor cells within patient blood, Cancer 
Letters. (2013). 
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2.1 Abstract  
 
Personalized medicine holds great promise for cancer treatment, with the potential to 
address challenges associated with drug resistance and interpatient variability. 
Circulating tumor cells (CTC) can be useful for screening cancer drugs as they may 
reflect the severity and heterogeneity of primary tumors. Here we present a platform 
for rapidly evaluating individualized drug susceptibility. Treatment efficacy is 
evaluated directly in blood, employing a relevant environment for drug administration, 
and assessed by comparison of CTC counts in treated and control samples. Multiple 
drugs at varying concentrations are evaluated simultaneously to predict an appropriate 
therapy for individual patients.  
 
Keywords: personalized medicine, circulating tumor cell, chemotherapy, drug 
resistance 
 
2.2. Introduction 
It is increasingly apparent that the most effective treatment for a cancer patient 
is a personalized approach based on predictive criteria for that individual. Traditional 
practice to achieve this goal has been to identify predictors of sensitivity or resistance 
in malignant cells. For example, it has been shown that panitumumab can be an 
effective therapy for colorectal cancer patients, but only in patients without KRAS 
mutation, which renders the treatment ineffective [1]. Thus, patients are screened for 
mutated KRAS prior to pantumumab treatment. Patients with non-small-cell lung 
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cancer are evaluated for specifically mutated EGFR prior to being placed on gefitinib 
[2]. However, for more general chemotherapeutics, such as taxanes, no single 
mutation or marker has been identified that will serve as a reliable predictor of patient 
response. Chemotherapeutic resistance, both intrinsic and acquired, is a significant 
problem and is believed to result in failure in more than 90% of patients with 
metastatic disease [3]. In an attempt to determine patient-specific sensitivity to 
cytotoxic and cytostatic agents, studies have been conducted wherein tumor cells are 
biopsied and treated ex vivo. Unfortunately no significant benefit has been found in 
these types of assays because sensitivity ex vivo does not necessarily translate to a 
similar response in vivo [4]. This is likely due in part to spatial heterogeneity within 
tumors and the fact that biopsies only sample a small section of a tumor [5; 6], and in 
part a consequence of the environment in which the cells are treated [7]. 
In recent years, much interest has been focused on circulating tumor cells 
(CTC) [8]. Many studies have found that CTC appear early in the disease, and their 
prevalence in blood correlates with disease severity [9; 10; 11; 12]. Clinicians are 
beginning to view CTC isolated from blood draws as a ‘fluid biopsy,’ something of a 
snapshot of the current state of a dynamic tumor, and CTC are believed to reflect in 
some way the breadth of tumor heterogeneity [13]. Indeed, the case has been made 
that CTC are the relevant cancer cell subpopulation to target for therapy based on the 
fact that 90% of cancer deaths are due to metastasis [14]. In addition, the circulatory 
system, within which cancer cells are termed CTC, is the primary route of metastasis 
[15]. As such, CTC are being investigated on a patient-to-patient level for 
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characterization purposes, such as epithelial-to-mesenchymal (EMT) state [16] and 
detection of surface markers that correlate with specific drug response [17]. 
We recently reported a technique for the isolation of CTC from patient blood 
in a relatively simple device using off-the-shelf components [18; 19]. The device is 
modeled on an inflamed postcapillary venule and is functionalized with recombinant 
human E-selectin to rapidly bind flowing cells and anti-EpCAM antibodies to firmly 
adhere cancer cells. It has been suggested that E-selectin plays a role in metastasis, 
specifically in the extravasation of metastatic cells [20; 21; 22]. In this paper we 
present a technique to rapidly screen patient samples for sensitivity to multiple 
chemotherapeutics in a relevant setting. To accomplish this, blood samples from a 
patient diagnosed with metastatic cancer are split into multiple aliquots with 
chemotherapeutics introduced at clinically relevant dosages to treat the CTC in situ. 
Subsequently, the CTC are isolated from the paired aliquots and enumerated. 
Reductions in CTC count are interpreted as drug sensitivities. This assumption was 
validated using drug-sensitive cell lines spiked into normal whole blood. It is 
concluded that one may successfully detect significant CTC count reductions using 
this approach, providing a platform upon which to make informed therapeutic 
decisions. This technique has the potential for additional use as a companion tool to 
detect acquired resistance throughout treatment.  
 
2.3 Materials and Methods 
2.3.1 Cell culture 
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BT20 and PC3 cells were purchased from the American Type Culture Collection 
(ATCC). BT20 cells were grown in Eagle’s Modified Medium (ATCC, Manassas, 
VA) supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals, 
Lawrenceville, GA) and 1% penicillin-streptomycin (Lonza, Basel, Switzerland). PC3 
cells were grown in RPMI 1640 media (VWR, Randor, PA) supplemented with 10% 
FBS and 1% penicillin-streptomycin. Cells were maintained at 37°C and 5% CO2. 
 
2.3.2 Antibodies and reagents 
Anti-EpCAM (clone 158210), anti-EpCAM-FITC (clone 158206) antibodies and 
recombinant human-E-selectin were purchased from R&D Systems (Minneapolis, 
MN). Anti-CD45-APC (clone HI30) antibody and Annexin V-APC kit were obtained 
from BD Biosciences (San Jose, CA). Anti-EpCAM-FITC (clone HEA-125) was 
obtained from Miltenyi Biotec (Auburn, CA). Halloysite nanotubes were a gift from 
NaturalNano (Rochester, NY). Ficoll-Paque was purchased from GE Healthcare 
(Waukesha, WI). Erythrocyte lysis buffer was obtained from Qaigen (Germantown, 
MD). Docetaxel, mitoxantrone, and calcium carbonate were purchased from Sigma 
Aldrich (St. Louis, MO). Doxorubicin was purchased from Sellek-Pfizer (Houston, 
TX). ViaCount Viability Kit was purchased from Millipore (Billerica, MA). Hank’s 
balanced salt solution (HBSS), phosphate-buffered saline (PBS), PBS supplemented 
with calcium and magnesium, and trypsin were purchased from Life Technologies 
(Grand Island, NY). Paraformaldehyde was acquired from Electron Micropscopy 
Sciences (Hatfield, PA). DAPI was obtained from Vector Laboratories (Burlingame, 
CA). Bovine serum albumin (BSA) was purchased from Sigma Aldrich (St. Louis, 
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MO). Dimethyl sulfoxide (DMSO) was obtained from Avantor Performance Materials 
Inc. (Center Valley, PA).  
 
2.3.3 Spiking of cancer cell line cells into blood 
Figure 2.1 Schematic of CTC analysis protocol. 
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Cancer cell line cells were spiked in blood, treated with chemotherapeutic drugs, and 
then isolated. This process is depicted schematically in Fig. 2.1. Peripheral blood was 
drawn from healthy volunteers after informed consent and transferred to 8 mL 
polystyrene round-bottomed tubes (BD Biosciences) in which the interior lumen had 
been blocked with 3% BSA for 1 h at room temperature. 50,000 breast cancer (BT20) 
or prostate cancer (PC3) cells were added to 5 mL of blood. The spiked blood was 
then treated with vehicle control (dimethylsulfoxide, DMSO) or one of three drug 
dosages based on published pharmacokinetic data (20% of peak plasma concentration 
(PPC), 100% PPC, and 300% PPC). Breast cancer spiked blood was treated with 
docetaxel (1 ug/mL, 5 ug/mL, 15 ug/mL) or doxorubicin (0.2 ug/mL, 1 ug/mL, 3 
ug/mL); prostate cancer spiked blood was treated with docetaxel or mitoxantrone (0.1 
ug/mL, 0.5 ug/mL, 1.5 ug/mL). Peak plasma concentrations were determined by 
previous pharmacokinetic studies [18-20]. Samples were incubated for 24 h at 37°C 
on a BioRad UltraRocker rocking platform (Hercules, CA).  
 
2.3.4 Preparation of selectin-functionalized microtubes  
Selectin-functionalized microtubes for cancer cell isolation were prepared as 
previously described [18,19]. Microrenathane tubing was washed with ethanol and 
distilled water, then coated with poly-L-lysine (1:250) and 6.6 wt% halloysite 
nanotubes. The tubes were subsequently washed with distilled water and allowed to 
cure overnight at RT. The halloysite-coated microtubes were then perfused with 20 
ug/mL Protein-G and allowed to incubate for 2 h at RT. A solution of 10 ug/mL E-
selectin-Fc chimera and 50 ug/mL anti-EpCAM antibody was then pulled into the 
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microtubes. The tubes incubated with this solution for 2 h at RT. The tubes were 
blocked with 5% milk for 1 h at RT. 
 
2.3.5 Cell isolation and enumeration from spiked blood 
Buffy coat was extracted from spiked blood using a Ficoll density centrifugation as 
previously described [18]. Briefly, buffy coat was washed in HBSS and any remaining 
red blood cells were lysed with erythrocyte lysis buffer for 10 min at room 
temperature (RT). Cells were washed with HBSS and resuspended in 2 mL of flow 
buffer. Flow buffer was prepared by saturating PBS containing Ca2+ and Mg2+ with 
CaCO3, followed by sterile filtration through a 0.2 µm PFTE syringe filter (Millipore). 
Cells were perfused through the selectin-functionalized microtube device a shear 
stress of 2 dyn/cm2. After flow, the microtube devices were washed with cell-free flow 
buffer, and adherent cells were removed from the tube by introducing trypsin for 10 
min at RT. The recovered cells were plated onto glass bottom petri dishes (Grenier 
Bioone, Frickenhausen, Germany) and allowed to recover in media supplemented with 
30% FBS for 4 h.  
Cells were fixed in 4% paraformaldehyde for 45 min at RT. Plates were incubated 
with anti-EpCAM antibody conjugated to FITC diluted 1:100 in PBS for 1 h at RT 
followed by incubation with anti-CD45-APC antibody diluted 1:100 for 45 min at RT. 
DAPI was added and the plates were imaged using an Olympus IX81 fluorescence 
microscope (Center Valley, PA) or Zeiss LSM710 confocal microscope (Oberkochen, 
Germany) within the Life Science Core Facility at Cornell University. Cell counts 
were based on EpCAM and CD45 expression, nucleus size and shape, and cell size 
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and morphology. A CTC was taken as any cell that met the following requirements: 
greater than 8 um in size, nonsymmetrical nucleus, positive for EpCAM, negative for 
CD45. Fluorescent micrographs were taken at 20 randomly selected locations within 
each well, and total cell counts estimated based on the total well area [18]. 
Processed cells that were not captured in the tube were collected, washed with PBS, 
and incubated with anti-EpCAM-FITC (clone 158206) for 1 h at RT. Stained cells 
were subsequently washed and stained with annexin-V and propidium iodide 
according to manufacturer instructions. Quantification was carried out using a 
Millipore Guava Easycyte flow cytometer. 
 
2.3.6 Patient sample isolation 
Two tubes of peripheral whole blood (7.5 mL per tube) was collected from patients 
diagnosed with stage IV cancer by BioCytics Inc. at Carolina BioOncology Institute, 
PLLC, after informed consent. Samples were analyzed from 3 breast cancer patients 
(Br1 through Br3), 2 prostate cancer patients (Pr1 and Pr2), one renal cancer patient 
(Re1), and one colon cancer patient (Co1). Samples were shipped overnight to Cornell 
University where they were split into 3 2.5 mL samples and treated with vehicle 
control, subclinical (20% PPC), or clinical dosages (100% PPC) of drug. Drugs were 
selected based on the cancer type. Prostate samples were treated with docetaxel and 
mitoxantrone; breast, colon, and renal samples were treated with docetaxel and 
doxorubicin. Samples were processed and enumerated in the precise manner as in cell 
spiking experiments as described above.  
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2.3.7 EpCAM expression following drug treatment 
In order to determine whether the reduction in captured cells was from cell death or 
loss of adhesion ability, the expression of EpCAM was measured after drug treatment. 
BT20 and PC3 cells were plated on 24 well plates. Cells were treated with the same 
dosages and drugs as in blood spiking experiments. The plates were incubated for 4 h 
at 37°C. The cells were released from the plates with trypsin and then allowed to 
recover for 1 h at 37°C.  Cells were stained with a 1:100 dilution of anti-EpCAM 
conjugated with FITC (clone HEA-125) for 30 minutes on ice. Cells were washed 
twice with buffer and analyzed using a flow cytometer.  
 
2.3.8 Cell viability 
Cells were plated on 24 well plates and treated with drug at the same concentrations 
used in the isolation studies for 24 h at 37°C. Cells were released from the plate with 
trypsin and washed with buffer. Cells were then diluted 1:10 in ViaCount viability 
reagent and incubated for 10 min at RT, according to the manufacturer instructions. 
The samples were then processed on a flow cytometer using built-in ViaCount 
software.  
 
2.3.9 Statistics 
All graphical error bars represent standard error of the mean. Significance was 
determined by performing an unpaired two-tailed t-test with α=0.05 in GraphPad 
Prism.  
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2.4. Results 
2.4.1 BT20 and PC3 cells showed dose dependent susceptibility to chemotherapeutic 
drugs in vitro. 
Chemotherapeutic drugs of interest (docetaxel, doxorubicin, mitoxantrone) were tested 
for their efficacy in vitro prior to testing the drugs in situ in whole blood (Fig. 2). Data 
are expressed as the number of viable cells relative to the untreated sample. BT20 
showed dose-dependence, and this effect reached a plateau at ~50% viability with 
docetaxel. A similar effect occurred with docetaxel on PC3. Extended dose 
dependence was seen with doxorubicin and BT20 as well as with mitoxantrone and 
PC3, where viability was reduced to 3 and 1.5%, respectively. 
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2.4.2 BT20 and PC3 cells showed drug dependent susceptibility to chemotherapeutic 
drugs in whole blood.  
50,000 BT20 or PC3 cells were spiked into whole blood, treated with appropriate 
chemotherapeutic drug, and isolated as described above. The clinical dosage of each 
drug was taken to be the maximum plasma concentration determined by previous 
pharmacokinetic studies [18-20]. BT20 cells were treated with docetaxel (1 ug/mL, 5 
ug/mL, 15 ug/mL) and doxorubicin (0.2 ug/mL, 1 ug/mL, 3 ug/mL). Cell counts of 
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Figure 2.2. Breast and prostate cancer cell lines are sensitive to docetaxel, 
doxorubicin, and mitoxantrone in vitro. Results are presented as the ratio of 
viable cells following 24 h of drug administration to the number of viable cells in 
the control sample. (A) BT20 cells treated with docetaxel. (B) BT20 cells treated 
with doxorubicin. (C) PC3 cells treated with docetaxel. (D) PC3 cells treated with 
mitoxantrone. Figures are representative of two independent experiments. 
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BT20 treated with docetaxel were reduced to 70.2±5.4% (mean±SEM), 43.9±2.7%, 
and 47.7±4.1% of the untreated sample. When treated with doxorubicin, cell counts 
decreased to 83.9±3.8%, 59.9±3.0%, and 52.4±2.5%, with respect to the untreated 
control. PC3 cells were treated with docetaxel and mitoxantrone (0.1 ug/mL, 0.5 
ug/mL, 1.5 ug/mL). Docetaxel treatment of PC3 cells reduced the cell count to 
86.3±7.1%, 41.7±4.4%, and 60.3±6.2 of control, while mitoxantrone treatment counts 
were 86.1±8.0%, 54.7±5.9%, and 54.5±6.2% of the untreated control (Fig. 2.3, Table 
2.1).  
To confirm that the uncaptured cells were indeed rendered not viable rather than just 
non-adhesive, the cells from the syringe that did not stick to the tube were stained with 
annexin-V and propidium iodide. No significant number of viable EpCAM-positive 
cells were observed in any of the samples studied (data not shown).  
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Figure 2.3. Breast and prostate cancer cell lines were spiked into 5 mL whole blood and 
treated with various doses of drugs. Following 24 h incubation, cancer cells were isolated 
from the blood and enumerated. Results are presented with individual donor data 
represented by black lines and the mean capture by a red dotted line. (A) BT20 cells treated 
with docetaxel. (B) BT20 cells treated with doxorubicin. (C) PC3 cells treated with docetaxel. 
(D) PC3 cells treated with mitoxantrone. (E) Representative micrographs of PC3 cells 
captured from blood samples treated with docetaxel. Cells were stained for EpCAM (green), 
CD45 (red), and nucleus (DAPI). Error bars represent standard error of the mean. * P < 
0.05, ** P < 0.01, *** P < 0.001; scale bar = 50 um 
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Table 2.1. Experimental data detailing the number of cells captured from cell spiking 
in whole blood. PPC = 5 ug/mL docetaxel (DT), 1 ug/mL doxorubicin (DOX), and 0.5 
ug/mL mitoxantrone (MTX).  
 
2.4.3 Chemotherapeutic drug treatment of BT20 and PC3 cells did not cause loss of 
EpCAM expression. 
It was investigated whether the reduction of isolated cells as a result of drug treatment 
was due to drug efficacy or to simply loss of adhesion markers. To address this, the 
Cell 
Line 
Treatment Donor Control 20% PPC 100% PPC 300% PPC 
BT20 DT A 1522 ± 136 987 ± 81 487 ± 42 820 ± 114 
BT20 DT B 2597 ± 186 2222 ± 289 1347 ± 97 1469 ± 173 
BT20 DT C 1906 ± 139 1147 ± 82 914 ± 67 624 ± 45 
BT20 DOX A 2276 ± 116 2717 ± 142 1857 ± 118 1883 ± 110 
BT20 DOX B 2539 ± 121 2499 ± 103 1228 ± 100 837 ± 59 
BT20 DOX C 1521 ± 72 514 ± 50 754 ± 51 632 ± 33 
PC3 DT A 1251 ± 112 890 ± 105 500 ± 68 1043 ± 120 
PC3 DT B 4260 ± 437 4095 ± 300 2006 ± 355 2006 ± 455 
PC3 DT C 3992 ± 422 3662 ± 400 1512 ± 184 2020 ± 241 
PC3 MTX A 6019 ± 572 4178 ± 494 2529 ± 332 2419 ± 332 
PC3 MTX B 2419 ± 247 2721 ± 332 1759 ± 224 1127 ± 176 
PC3 MTX C 7778 ± 1039 5937 ± 518 3848 ± 690 5964 ± 861 
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surface expression of EpCAM was tested following drug treatment by flow cytometry 
(Fig. 2.4). No significant change in surface EpCAM expression was seen post-
treatment for any of the drug concentrations. This suggests that the reduced cell counts 
in drug treated samples were due to reduction in the number of viable cells rather than 
a loss of adhesion affinity per se.  
 
2.3.4 Primary cancer blood samples show heterogeneous susceptibility to 
chemotherapeutic drugs. 
To investigate the relevance of this platform for clinical use, we tested primary blood 
samples from 7 cancer patients (3 breast, 2 prostate, 1 colon, 1 renal). Subclinical and 
clinical dosages were tested. Breast, colon, and renal  
Figure 2.4. EpCAM expression of BT20 and PC3 did not change following 
treatment with docetaxel, doxorubicin, or mitoxantrone, as evaluated by flow 
cytometry. Data is presented in histograms wherein the black shaded region 
represents isotype control, the blue line is the control untreated sample, the red 
line is the 20% PPC, the orange line is 100% PPC, and the green line is 300% 
PPC. (A) BT20 cells treated with docetaxel. (B) BT20 cells treated with 
doxorubicin. (C) PC3 cells treated with docetaxel. (D) PC3 cells treated with 
mitoxantrone. Figures are representative of two independent experiments. 
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Figure 2.5. Peripheral blood from patient samples showed heterogeneous sensitivity 
to chemotherapeutics. Patient samples were collected from three breast cancer 
patients (Br1, Br2, and Br3), two prostate cancer patients (Pr1 and Pr2), one renal 
and one colon cancer patient (Re1 and Co1, respectively). Each tube of whole blood 
was split into three aliquots and treated with vehicle control, 20% PPC, or 100% PPC 
of the appropriate drug. DT = docetaxel, DOX = doxorubicin, MTX = mitoxantrone. 
Error bars represent standard error of the mean. * P < 0.05, ** P < 0.01, *** P < 
  49 
blood samples were treated with docetaxel and doxorubicin, while prostate cancer 
blood was treated with docetaxel and mitoxantrone (Fig 2.5; Table 2.2.). Overall, drug 
susceptibility for at least one of the drugs tested in 6 of 7 patients was detected. 3 
patients were susceptible to only one of the drugs tested (Co1, Re1, Br3) while 3 were 
susceptible to both (Br1, Br2, Pr2). The remaining patient (Pr1) was not susceptible to 
either drug tested.  
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Table 2.2. Experimental data the number of cells captured from cancer patient blood 
samples. PPC = 5 ug/mL docetaxel (DT), 1 ug/mL doxorubicin (DOX), and 0.5 ug/mL 
mitoxantrone (MTX).  
Donor Treatment Control 20% PPC 100% PPC 
Br1 DT 7998 ± 905 2336 ± 255 1759 ± 423 
Br1 DOX 4672 ± 609 --   -- 715 ± 120 
Br2 DT 4288 ± 423 3188 ± 365 1429 ± 241 
Br2 DOX 3188 ± 318 3106 ± 563 989 ± 167 
Br3 DT 9372 ± 550 5552 ± 550 7861 ± 879 
Br3 DOX 8273 ± 533 4453 ± 449 3710 ± 473 
Pr1 DT 7476 ± 524 9455 ± 1093 8768 ± 1070 
Pr1 MTX 8300 ± 603 7146 ± 722 7531 ± 886 
Pr2 DT 110765 ± 10336 52826 ± 5043 74952 ± 4918 
Pr2 MTX 156087 ± 10276 87622 ± 9860 52606 ± 8115 
Re1 DT 13486 ± 576 11076 ± 1011 12423 ± 1345 
Re1 DOX 11269 ± 1034 6019 ± 486 5882 ± 843 
Co1 DT 2749 ± 255 2529 ± 247 1072 ± 205 
Co1 DOX 2446 ± 209 1292 ± 140 1677 ± 332 
 
2.4. Discussion 
In this paper a novel platform is presented for the prediction of cancer drug efficacy on 
a patient-to-patient basis, in a manner suitable for pre-screening prior to systemic 
administration. This platform was first characterized by spiking breast and prostate 
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cancer cell lines at known quantities into healthy blood, creating model samples of 
blood containing cancer cells with well-defined susceptibilities. Based on studies of 
drug efficacy on these cell lines in media (Fig. 2.2), we were able to recapitulate the 
therapeutic effect in whole blood (Fig. 2.3). It is interesting to note that the effect of 
doxorubicin and mitoxantrone at their highest dosages was to eliminate nearly all 
cancer cells in media, however in whole blood there was no significant increase in cell 
elimination in response to the the clinical dosage. The observed limit of efficacy to 
about 50% viability is likely due to various factors present in the milieu of whole 
blood. This underscores another advantage of our system, specifically that drug 
efficacy may be tested in the same environment in which it is actually administered. 
The dose dependence of treatment observed also demonstrates that it may be possible 
to identify patients that would respond to subclinical dosages at a level of efficiency 
equal to the maximum dosage, ameliorating detrimental side effects associated with 
chemotherapeutic toxicity. 
A high degree of spiked cancer cell death was observed following incubation of blood 
samples for 24 h on a rocker. This is most likely due in part to the fact that the test 
tubes were thoroughly blocked with BSA and the motion of the blood from the rocker 
prohibited cell adhesion, contributing to in cell death via anoikis [23; 24]. Further cell 
death is likely the result of inhospitable factors within the whole blood collected from 
healthy volunteers, which would explain the relatively high degree of variability 
between donors (Table 2.1). Nonetheless, we were able to detect a therapeutic 
reduction in cell number, which is significant due to the fact that all comparative 
samples were matched. This is not expected to be the case for clinical samples since 
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the cancer cells are not foreign transplants from a different donor but native to the 
patient, and, additionally, primary cancer cells have been shown to avoid anoikis by 
various mechanisms [24; 25], and can escape immune activity [26; 27; 28]. 
Significant quantities of CTC were detected in blood samples of 7 patients diagnosed 
with metastatic cancer (Fig. 2.5). Of these, 6 showed a marked reduction in CTC count 
following enumeration, and of these 6 samples, three of them showed CTC reduction 
in response to one of the two drugs tested. The fact that 3 out of 7 of the samples 
responded differently to different drugs when treated in an identical manner otherwise 
suggests that these results are in fact due to sensitivities and resistances of the CTC. It 
is possible that in this case the differential sensitivities could be due to patients’ 
previous treatment protocols. While all of the patient samples analyzed showed 
distinctly high CTC counts, one patient had exceptionally high counts: Pr2. It is 
interesting to note that Pr2, which showed much higher CTC counts than Pr1, also had 
a much higher PSA level of 2,149 ng/mL compared to 643 ng/mL for Pr1. It remains 
to be seen if our technique provides a true predictor of therapeutic response of primary 
tumor and metastatic lesions. Nevertheless, the assay is intended to be carried out in a 
relevant biological environment rather than an engineered environment, which may be 
a necessary step to development of a successful predictive clinical tool. 
Clinical trials have been performed and more are in progress that monitor CTC count 
throughout the treatment of different cohorts of patients. It has been shown that CTC 
count is a reliable predictor of response and relapse [29; 30].  The combination of 
these clinical trial findings with the suggestion that CTC may be the most deadly 
subpopulation of cancer cells (in that they propagate metastasis) makes CTC a 
  53 
particularly promising substrate for the development of personalized medicine 
determination in the clinic [31]. The assay developed here has the potential to be used 
in a number of ways. Patient cohorts could be selected based on drug resistance pre-
screening. Alternatively, acquired resistance to chemotherapeutics can be monitored 
throughout the progress of clinical trials. Furthermore, as we have shown here for the 
administration of docetaxel and doxorubicin to renal and colon cancers, this platform 
allows for rapid screening of drugs approved for some cancers but remaining to be 
evaluated for others. This is particularly useful considering recent observations by the 
Cancer Genome Atlas Research Network that cancers from different tissues can have 
strikingly similar genetic signatures [32; 33]. 
In conclusion, we have developed a novel platform for screening drug efficacies of 
chemotherapeutics using CTC enumeration as a diagnostic output as a predictor for 
drug resistance in individual patients. BT20 and PC3 cells were spiked into whole 
blood and treated with the purpose of validating this technique. The assay is carried 
out in a rapid procedure that, in a clinical setting, could predict a patient’s sensitivity 
in a single day. Two doses of two therapeutic agents simultaneously; scale up to test 
more drugs is limited only by the quantity of blood that can be drawn from a patient 
and the required sample volume per test. Additionally, this technique is not limited to 
the isolation technique used in this paper; it can be adapted to any chip-based or 
magnetic bead-based CTC isolation method. 
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Chapter 3 
 
Primary Circulating Tumor Cells Isolated from Peripheral Blood 
Demonstrate Sensitivity to Novel TRAIL Liposomal 
Therapeutic 
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3.1 Introduction 
Cancer metastasis accounts for the majority of all cancer related fatalities (1). While 
therapies against primary tumors have progressed significantly in the last few decades, 
therapies to treat or prevent metastasis are lacking.  
Metastasis occurs when cells from the primary tumor break off from the primary 
tumor and migrate to the vasculature. Cells then intravasate into a vessel, where they 
then become circulating tumor cells (CTC). CTCs travel through the bloodstream 
where they interact with immune cells and the endothelium. When they encounter the 
correct proteins on the endothelium, they are able to roll and adhere, extravasating out 
of the bloodstream, to a distant site(2).  
Circulating tumor cells are thought to reflect the complexity and breadth of primary 
tumors, even more than traditional biopsies. For this reason, CTCs tend to be 
considered liquid biopsies. While currently CTCs are only used clinically to determine 
prognosis for many cancer types (3–7), CTCs hold significant potential as both 
diagnostic and treatment targets.  
Studies have shown that CTC can be helpful in tracking or determining a patient’s 
response to therapy. For example, Nolé et al showed that breast cancer patients with 
CTC counts higher than 5 before and after chemotherapy had worse prognosis than 
those with counts of less than 5 (8). The DETECT study aimed to use CTC status and 
genetic markers to direct personalized treatment (9). Additionally, the Haber group 
showed that cultured CTC could be used to test drug sensitivity (10).  
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We previously reported on a novel broad application diagnostic test using CTC 
enumeration to test for drug sensitivity. In this test, drugs are added directly to whole 
blood and CTC are enumerated and compared to a control sample. A reduction in CTC 
count is considered a show of sensitivity (11).  
While progress has been made on the diagnostic use of CTC, still very few drugs have 
been created to target CTC. We recently described a novel liposomal therapeutic 
targeting CTC. The drug is comprised of a phosphatidyl choline (PC)-based liposome 
functionalized with two proteins, E-selectin, a natural adhesion protein found on the 
surface of activated endothelium, and TNF-related apoptosis inducing ligand (TRAIL) 
(12). TRAIL is an apoptotic protein constitutively expressed by a variety of cells, 
including various immune cells. Studies have shown that tumor cells have increased 
susceptibility to TRAIL and that the majority of normal cells show no sensitivity (13). 
In one study, TRAIL was shown to have a cytotoxic effect on 16 different cancer cell 
lines, yet exhibit no obvious signs of toxicity when injected into primates (14). 
Additionally, blockage of TRAIL in a mouse tumor model increased the occurrence of 
liver metastases (15).  
The one drawback of TRAIL therapies is the short half-life of soluble TRAIL; TRAIL 
only remains in the body for approximately 30 minutes. (14) However, we found that 
when functionalized to a liposome, the half-life of the therapy is much longer. In a 
pharmacokinetic study in mice, we showed the presence of EST liposomes 72 hours 
after injection (16). Additionally, EST liposomes were shown to eradicate over 99% of 
CTC after tail vein injection in nude mice. Mice treated with EST liposomes also 
showed presence of apoptotic cancer cells within the lungs (12). In a prostate model of 
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metastasis, EST liposome treatment was shown to block widespread metastasis, as 
well as decreased the CTC count and the size of the primary tumor (16). 
While the EST liposome therapy shows great promise in vitro and in vivo against 
cancer cell lines, the efficacy of the therapy on primary CTC has not been proven. 
Here, we use our previously described method to test drug efficacy to determine the 
sensitivity of human primary CTC to EST liposomes. We show that treatment of 
whole blood with EST liposomes decreases the number of viable CTC. 
 
3.2 Methods 
3.2.1 Cell Culture 
SW620 and Colo205 colon cancer cells were obtained from the American Type 
Culture Collection (ATCC). Colo205 cells were cultured in RPMI1640 supplemented 
with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (PS). SW620 cells 
were cultured in Lebowitz’s-15 media supplemented with 10% FBS and 1% PS. All 
cells were grown under humid conditions in 5% CO2 at 37°C. 
 
3.2.2 Liposome Formation and Functionalization 
Unilamellar liposomes were created as described previously (12). L-α-
lysophosphatidylcholine (Egg PC), egg sphingomyelin (Egg SM), ovine wool 
cholesterol (Chol) and 1,2 dioleoyl-sn-glycero-3-[N-(5-amino-1-
carboxypentyl)iminodiacetic acid) succinyl](nickel salt) were combine at weight ratios 
50%:30%:10%:10% and held under vacuum for 18 h to create thin lipid film. The film 
was then hydrated with liposome buffer (150 mM NaCl, 10mM Hepes, and 1 mM 
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MgCl2 in water) to create multilamellar liposomes. To create unilamellar liposomes of 
the desired size (100nm), liposomes were subjected to 10 freeze thaw cycles followed 
by two subsequent rounds of extrusion at 60°C through polycarbonate membranes 
with 200 nm and 100 nm pore size, respectively. Fresh liposomes were then incubated 
with recombinant human ES and TRAIL at final concentrations of 71.43 nM and 250 
nM respectively at 37°C for 30 minutes. ES and TRAIL both contained a his-tag and 
were able to bind to the Ni-NTA lipid on the surface of the liposome. Liposomes were 
stored at 4°C overnight and used within two weeks to decrease the chance of oxidation 
of lipids. 
 
3.2.3 Cell Spiking Treatment 
100,000 Colo205 cells were spiked into 4 mL aliquots of blood from healthy human 
donors. Cells were incorporated for 15 min on a rotator. Blood aliquots were then 
treated with 20-50 μL/mL liposome buffer, E-selectin/TRAIL liposomes (EST), or 1 
μg/mL soluble recombinant human TRAIL (sTRAIL). Treated blood samples were 
placed on a rotator at room temperature (RT) overnight.  
 
3.2.4 Primary blood treatment 
8 mL blood samples were obtained from stage IV cancer patients at Guthrie Medical 
Center or Rochester University. Blood was split into 4 mL aliquots and placed into 
tubes pre-blocked with 3% bovine serum albumin (BSA). Blood was then treated with 
50 μL/mL liposome buffer or EST liposomes. Blood was incubated overnight on 
rotator at RT. 
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3.2.5 Circulating tumor cell isolation 
Whole blood was carefully layered onto Ficoll-Pacque and centrifuged at 2000xg for 
15 min with no brake. Buffy coat was extracted using a Pasteur pipet and washed with 
Hank’s Buffered Saline Solution (HBSS-) with no Ca2+/Mg2+. Residual erthyrocytes 
were lysed with erythrocyte lysis buffer for 10 min and subsequently washed with 
HBSS-. Resulting buffy coat was then resuspended in 80 μL per 107 cells of MACS 
buffer (PBS with 0.5% BSA, 2mM EDTA). 20 μL per 107 cells of anti-CD45 
magnetic beads (Miltentyi Biotec) was added and solution was incubated for 15 min at 
4°C. Magnetic cell solution was washed with additional MACS buffer then 
resuspended in 500 μL fresh buffer and loaded into a primed magnetic MS column. 
Once the cell solution was completely through the column, the column was rinsed 3 
times with MACS buffer. The solution that came through the column is centrifuged at 
300xg for 8-10 min. The cell pellet was fixed in 4% paraformaldehyde for 20 min at 
RT. After washing CTC were deposited onto glass slides using Cytospin at 1000 RPM 
for 4 min.  
 
3.2.6 CTC Labeling and Imaging 
CTC on cytospun slides were first labeled with PI for 15 min at RT to identify any 
apoptotic cells. Slides were washed with phosphate buffered saline (PBS) 3 times. 
Anti-cytokeratin-FITC at 1:10 dilution in 0.5% Triton-X was added to the slides for 15 
min at RT. Slides were washed with PBS 3 times and then allowed to dry. Mounting 
media with DAPI was added to the slides and coverslips were placed.  Slides were 
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imaged using inverted Zeiss 880 confocal microscope in the Cornell Imaging Core 
Facility using 32 times magnification. Viable and apoptotic CTC were enumerated 
based on staining profiles. Viable CTC were determined to be cells with large nuclei, 
PI-, CK+. Apoptotic CTC were considered cells with large nuclei, PI+, CK+.  
 
3.3 Results 
3.3.1 SW620 cell count was reduced by treatment with EST liposomes in whole blood 
10,000 SW620 colon cancer cells were labeled with CellTracker Green and spiked 
into whole blood from healthy donors. Blood was treated with 20 μL/mL liposome 
buffer (vehicle control) or EST liposomes. The cell count in the treated sample was 
reduced by 85% when compared to the vehicle control, showing that the EST 
liposomes are effective at killing the SW620 cells (Figure 3.1).  
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Figure 3.1. SW620 cells are sensitive to EST liposomes in whole blood. 10,000 
SW620 cells were spiked into healthy whole blood and treated with EST liposomes. 
The number of cells recovered after treatment is shown. Error bars designate the 
standard deviation. Significance was determined using an unpaired, two-tailed t-test 
where * represents p<0.05.  
 
3.3.2 Patient Demographics 
Patients were selected based on cancer stage. All patients were suffering from Stage 
IV solid tumors and being treated at Guthrie Medical Center or Rochester University. 
Specific demographics for each patient can be seen in Table 3.1.  
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Table 3.1. Cancer Patient Demographics 
Patient Number Gender Age Primary Location 
097 M 41 Cholangiocarcinoma 
121* M 69 Prostate 
123* F 46 Breast 
125 M 67 Renal 
127* F 61 Pancreatic 
128* M 53 Colon 
129* M 37 Melanoma 
130 M 63 Prostate 
131 F 55 Breast 
132 F 86 Pancreatic 
202   Prostate 
*Excluded due to no viable CTC in control sample 
 
3.3.3 Primary CTC are sensitive to EST liposome treatment 
Blood was collected from 11 patients with stage IV cancer during routine visits at 
Guthrie Medical Center or Rochester University. The blood was split into two aliquots 
and one was treated with EST liposomes while the other served as the vehicle control. 
After overnight treatment, CTC were isolated using CD45-positive cell depletion. 
CTC enumeration was conducted based on positive cytokeratin staining. Viability was 
assessed based on PI exclusion. 6 of11 patients had viable CTC in control sample and 
were therefore evaluated for EST liposome sensitivity. All six patients saw a greater 
than 50% reduction in viable CTC with treatment (Figure 3.2, Table 3.2). Counts are 
shown as average ± standard error of the mean. Patient 097 showed the most 
sensitivity with 3756.8±560.8 viable cells in the vehicle control reduced to 11.1 ±'11.1'viable'cells'in'the'treated'sample'(Figure'3.3).''''
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Table 3.2. Cell Counts and Viability from Patient Blood EST Treatment  
Patient 
Number 
Vehicle Control EST liposomes %Reduction 
Viable Cells Total CTC % Viable Total CTC % Viable 
097 3939.3±583.6 95 1474.5±257.0 1 99.7 
125 22.3±12.0 100 8.9±5.9 100 60.0 
130 111.3±18.5 90 120.2±20.7 3 96.3 
131 100.2±22.0 85 37.1±9.2 100 56.5 
132 2741.2±449.5 99 1713.7±171.7 52 67.2 
202 40.0±15.5 100 8.9±5.9 100 77.8 
 
Figure 3.2. EST Liposome treatment reduces primary human CTC count in 
patient cancer blood. Whole blood from Stage IV cancer patients was treated 
with 50 µL/mL EST liposomes overnight. Resulting CTC counts are shown.  
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Figure 3.3. Example micrographs from patient CTC enumeration. (A) Blood 
from patient 097 treated with vehicle control, (B) 097 EST liposomes, (C) 132 
vehicle control, (D) 132 EST liposomes. Colors correspond to cytokeratin 
(green) staining, PI (red), and DAPI (blue). Scale bars are 100 µm.  
 
3.4 Discussion 
In this study, we showed that EST liposomes are effective for treating primary human 
CTC. Whole blood from stage IV cancer patients treated with EST liposomes had over 
50% less CTC than blood treated with a vehicle control. This is the first study where 
EST liposomes have been used on primary patient cells.  
The ability for cancer cells to evade the immune system is one of the pivotal hallmarks 
of cancer (17). In the past decade, researchers have worked to develop therapeutics 
that reverse this action, thereby sensitizing cancer cells to immune action. This is done 
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by increasing the natural cytotoxicity of immune cells or by decreasing immune 
suppression by tumor cells (18). The therapeutic presented in this study presents a 
third mechanism of action, introduction of additional cytotoxic proteins to the surface 
of immune cells. This therapy holds great potential due to the fact that it works within 
the bloodstream eliminating CTC. CTC are believed to be the cells that cause 
metastases, which in turn account for the vast majority of cancer fatalities. Therefore, 
if CTC are targeted and eliminated, it should decrease the occurrence of metastases 
downstream. Additionally, previous in vivo work shows that the liposomal therapy 
caused apoptosis of lung metastases and decreased the size of primary tumors, 
suggesting that the functionalized leukocytes can migrate to tumor and metastatic sites 
(12).  
TRAIL is uniquely suited as a cancer therapeutic due to its built-in targeting of cancer 
cells (13). In this study, we presented for the first time that primary CTC from patient 
blood are sensitive to TRAIL. TRAIL-based therapies to date have been limited in 
their clinical use due to low levels of therapeutic killing (19). While many cancer cell 
lines have been shown to be highly sensitive to TRAIL (14,20,21), primary cancers 
are inherently resistant or gain resistance over time (22,23). Because of this, 
significant work has been done to develop and discover sensitizing agents that can 
increase the efficiency of the anti-tumor effect of TRAIL therapies. It was discovered 
that this could be achieved through the use of common chemotherapeutics as well as 
natural, non-toxic compounds including curcumin and aspirin (21). We are currently 
exploring whether the use of low dose curcumin can increase the sensitivity of primary 
CTC to TRAIL liposomes. However, many worry that these sensitizers could also 
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increase the sensitivity of normal cells to the therapies (19). To overcome this, 
sensitizing agents can be encapsulated into nanoparticles, like the liposomes presented 
in this study. In fact, positive results have already been seen with TRAIL nanoparticles 
encapsulating doxorubicin (24) and paclitaxel.  
Another limitation of recombinant TRAIL therapies is nonspecific aggregation of 
TRAIL molecules. Currently the recombinant TRAIL therapy used in clinic is 
dulanermin (19,25). As of 2014, dulanermin had been tested in two randomized 
control trials, showing no therapeutic advantage (26,27). It is believed this is due to 
the short half-life in the plasma as well as its inability to cluster death receptors, a 
necessary step for the formation of the DISC. Other recombinant TRAIL proteins, 
such as his-tagged TRAIL have been limited as well due to nonspecific aggregation of 
the TRAIL proteins (28,29). TRAIL is naturally expressed as a trimer molecule, which 
in turn facilitates the clustering of death receptors on the cancer cell allowing for the 
formation of the DISC. While his-tagged TRAIL is used in this study, the TRAIL is 
bound to the surface of a liposome using Ni-NTA chemistry and therefore unable to 
aggregate. Additionally, it is possible that the functionalization of many TRAIL 
molecules on the surface of the liposome is sufficient for DR clustering, though this 
has yet to be confirmed.  
While recombinant TRAIL therapies hold great promise as anti-tumor agents, their 
success is currently limited by a number of factors. The TRAIL/E-selectin 
functionalized liposomes presented in this study have the potential to overcome a 
number of these limitations including avoidance of nonspecific aggregation and ability 
to encapsulate sensitizers. Additionally, the liposomes fall into the optimal size for 
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taking advantage of the EPR effect, which can increase TRAIL efficiency towards 
cancer cells. More work is needed to determine whether this therapy would be 
effective in the clinic, but the potential is evident. 
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Chapter 4 
 
Primary Whole Blood from Stage IV Tumor Patients Contains 
Circulating Cancer-Associated Fibroblasts (cCAF) that Influence 
CTC Survival Under High Shear Conditions 
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4.1 Introduction 
Tumors are comprised of several different types of cells that serve various functions. 
Traditionally, most cancer research focused solely on epithelial tumor cells, but as 
more came to light about cancer progression and immune evasion, the importance of 
supporting cells came to be better understood. One cell type in particular that is of 
great importance to the progression and metastasis of cancer is the cancer-associated 
fibroblast (CAF).  
CAF are defined by their spindle-like morphology as well as expression of several 
markers including alpha smooth muscle actin (SMA), fibroblast specific protein 
(FSP), and fibroblast activation protein (FAP) (1,2). Evidence suggests that CAF are 
derived from the transdifferentiation of several different cell types, resident 
fibroblasts, bone marrow derived progenitor cells, epithelial cells, and possibly 
endothelial cells. While CAF share many features with normal myofibroblasts 
involved in wound healing, CAF persist in the tumor and are not removed by 
apoptosis (3). This is mainly due to the presence of cancer cells, which secrete growth 
factors, and other cytokines that cause the transdifferentiation of CAF and help the 
phenotype persist (3).  
Aside from assisting in preparing the metastatic niche, CAF have been implicated in a 
number of other aspects of cancer progression. Activated CAF secrete inflammatory 
signals that may induce EMT in cancer cells (4), as well as recruit immune cells to the 
tumor (5), and enhance angiogenesis (6,7). Studies have also shown that removal of 
CAF from tumor microenvironment improves tumor sensitivity to chemotherapeutics 
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(1). For example, breast cancer cells co-cultured with cancer-associated fibroblasts 
showed greater resistance to tamoxifen (8).  
Due to their tumor promoting nature, many groups have worked to develop 
therapeutics targeting CAF (9). Some of the more promising drugs target signals 
involved in the proliferation of CAF including PDGF receptor (1). A anti-FAP 
antibody (sibrotuzumab) was shown to selectively target cancers and no off target 
organ uptake was shown in a preliminary clinical trial (10), though no anti-tumor 
effect was seen with this particular antibody therapy (11).  
The Jain lab performed a study where they looked at whether stromal and supporting 
cells migrate alongside cancer cells (12). In this study, they injected fluorescent cancer 
cells into a GFP mouse and observed both cancer cells and GFP cells in the blood of 
the tumor-draining vein. Next, they transplanted a skin flap from a GFP mouse onto a 
non-GFP mouse and injected fluorescent cancer cells into the skin flap. Again, they 
found both cancer cells as well as GFP stromal cells in the tumor-draining vein. They 
also found GFP stromal cells in the metastases. This was the first study that showed 
evidence that cancer cells may bring their own “soil” with them (12).  
Until recently, there was no evidence that this phenomenon also happened in humans. 
In 2015, Ao et al detected the presence of circulating CAF cells (cCAF) in the blood 
of 88% of metastatic breast cancer patients, but only 23% of patients with localized 
breast cancer, suggesting the presence of cCAF may be related to metastasis (13). 
In this study, we confirm the presence of cCAF in whole blood from patients with 
stage IV cancer. We also show the first direct isolation of cCAF from whole blood. 
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Additionally, we demonstrate that the presence of cCAF in the blood may help protect 
CTC from death due to the high shear forces of blood flow.  
  
4.2 Methods 
4.2.1 Cell Culture 
PC3 cells were obtained from American Type Culture Collection (ATCC) and 
cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and 1% 
peniciliin-streptomycin (PS). All cells were grown under humidified conditions at 
37°C and 5% CO2. 
 
4.2.2 Circulating Cancer Associated Fibroblast (cCAF) Isolation 
Blood from stage IV cancer patients was layered onto Ficoll-Pacque and centrifuged at 
2000xg for 15 min with no brake. Buffy coat was removed with a Pasteur pipet and 
washed with Hank’s buffer saline solution with no Ca2+/Mg2+. If necessary, red blood 
cells were lysed for 10 min at room temperature (RT) with erthyrocyte lysis buffer. 
Clean buffy coat was resuspended in 80 μL of pre-cooled MACS buffer (PBS 
supplemented with 0.5% BSA and 2mM EDTA). 20 μL anti-fibroblast beads from 
Miltenyi Biotech were added and solution was incubated for 30 min at room 
temperature. Cells were washed with additional MACS buffer then loaded into MS 
magnetic column. Cells were pulled through the column by gravity and when the 
column it was rinsed by MACS buffer 3 times. The column was then removed from 
the magnet, 2 mL MACS buffer added, and cells in the column eluted with a plunger. 
After pelleting by centrifugation, cells were fixed in 4% paraformaldehyde for 20 min 
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at RT. Then cells were resuspended in PBS and deposited onto glass slides by 
Cytospin.  
 
4.2.3 Circulating tumor cell (CTC) Isolation 
Blood from stage IV cancer patients was layered on Ficoll-Pacque and centrifuged for 
15 min at 2000xg with no brake. Buffy coat layer was extracted using a Pasteur pipet 
and washed with HBSS. Erythrocytes were lysed with lysis buffer for 10 min and 
subsequently washed with HBSS. Buffy coat was resuspended in 80 μL of MACS 
buffer and 20 μL anti-CD45 magnetic beads for 15 min at 4°C. After washing with 
more MACS buffer, magnetic cell solution was added to MS column on magnet. Cells 
moved through column by gravity and column was subsequently washed 3X with 
MACS buffer. Cell and wash solution collection was spun down and pellet was fixed 
with 4% paraformaldehyde. Cells were placed onto slides using Cytospin at 1000 
RPM for 4 min.  
 
4.2.4 Fibroblast Staining and Imaging 
Cells deposited onto cytospun slides were first incubated in anti-smooth muscle actin 
antibody diluted 1:10 in 0.5% Triton-X for 20 min at RT. After 3 washed with PBS, a 
secondary antibody solution consisting of 10 μg/mL goat anti-mouse IgG-Alexa 594 
and 1:10 anti-cytokeratin-FITC diluted in 0.5% Triton-X was added to the slide and 
incubated for 20 min at RT in the dark. The slides were washed 3 additional times 
with PBS. Mounting media with DAPI was added to the slide and the slide was 
covered with a coverslip. Slides were stored at 4°C until imaging. Slides were imaged 
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in the Cornell Imaging Core Facility on a Zeiss inverted 880 confocal microscope with 
40X magnification.  
 
4.2.5 Primary Mouse CAF Isolation 
Single cell suspension of mouse tumor cells was a gift from Cynthia Reinhart-King. 
Tumor cell suspension was counted and resuspended in 90 μL of MACS buffer for 
every 107 cells with 10 μL anti-mouse CD45 beads for every 107 cells. Solution was 
incubated for 15 min at 4°C. Cells were washed then passed through an LS column 
that was rinsed 3 times. The column run through was centrifuged at 300xg for 10 min 
and the resulting pellet was resuspended in 90 μL of MACS buffer for every 107 cells. 
10 μL/107 cells of anti-mouse EpCAM beads were added and the solution was 
incubated for 15 min at 4°C. After washing the LS column separation was repeated. 
The flow through was pelleted and the cells were cultured in DMEM media 
supplemented with 4.5 g/L glucose, 10% FBS, and 1% PS. Presence of CAF was 
confirmed by flow cytometry.  
 
4.2.6 Flow Cytometry 
Cells at a concentration of 106/mL were incubated in an antibody solution (anti-rat 
IgG-PE, anti-mouse EpCAM-PE, anti-mouse CD45-PE, or anti-mouse PDGFRα-PE) 
for 30 minutes on ice. After 2-3 washes with PBS, cells were resuspended in PBS and 
analyzed using Millipore Guava EasyCyte flow cytometer. 
 
4.2.7 Microshear Pulsing 
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Cancer cells in a primary tumor are exposed to relatively low fluid shear stress (FSS) 
conditions (on the order of 0.1 dyn/cm2) exerted by interstitial flow (14). Once a CTC 
enters the vasculature, it is subjected to much higher shear conditions. Venous flow 
can have FSS of 1-6 dyn/cm2, while arterial flow shows FSS of 10-70 dyn/cm2 (15). 
Moreover, at certain areas of the vasculature, cells are exposed to very high levels of 
FSS (>1,000 dyn/cm2) (16,17), particularly during blood flow through the heart, vessel 
bifurcations, and in vessels of large diameter, for 1-30 milliseconds at a time (18–20). 
In order to successfully metastasize, a CTC must navigate and survive these high FSS. 
It has previously been shown that malignant cells have an inherent resistance to FSS 
(21). So as to test whether the presence of CAF could influence this resistance, we 
exposed prostate cancer cells grown alone and in the presence of CAF cells to 
millisecond pulses of high shear flow using a previously described method (21). PC3 
cells were labeled with Calcein-AM for 15 min at RT in the dark and washed 2 times 
with fresh media. Then, PC3 and mouse CAF cells were co-cultured for 48 hours 
under normal culture conditions at a ratio of 1:1. Cells were lifted and resuspended at 
500,000 cells/mL. Once the number of PC3 cells had been determined in each sample 
using flow cytometry, the volume equivalent for 200,000 PC3 cells was placed into a 
syringe and pumped through a 30G-½ in needle. This process was repeated every 2 
min, to mimic the physiological conditions of high shear exposure (21), for a total of 
5-10 shear rounds. Cells were then plated in serum-free media overnight to allow for 
cell death to complete. The following day, the number of fluorescent PC3 cells 
remaining was counted using flow cytometry. 
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4.3 Results 
4.3.1 CTC Fractions contain cancer-associated fibroblasts  
CTC were isolated from primary human blood drawn from patients diagnosed with 
Stage IV cancer. Cells were placed into culture. Upon inspection of the cell cultures, 
two morphological states were observed. Images of the cultures can be seen in Figure 
4.1. Red arrows show the rounded morphological state; black arrows indicate the 
elongated, spindle-like morphology. Based on the morphological characteristics, it 
was believed the long, spindle-like cells might be fibroblasts. 
Figure 4.1. CTC cultures contain cells of two different morphological states. 
CTC isolated from stage IV cancer patients were cultured for several days. 
Phase contrast images were taken on a Zeiss IX81 microscope. Black arrows 
indicate cells with elongated, spindle-like morphology, red arrows indicate 
round morphology. Scale bar represents 25 µm. 
 
To confirm the presence of fibroblasts in the CTC fractions, CTC isolated from cancer 
patients was stained for the presence of smooth muscle actin (SMA), a known cancer-
associated fibroblast (CAF) marker, as well as cytokeratin (CK), a CTC marker. Cells 
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were imaged at high magnification using a confocal microscope. Both SMA- and CK-
positive cells were seen in the patient CTC fractions. As shown in Figure 4.2, SMA-
positive cells exist both as single cells as well as part of clusters.  
 
Figure 4.2. CTC fractions contain cells that are SMA+. CTC fractions from 
stage IV cancer patients were imaged for the presence of CAF cells. Cells 
were stained for SMA (red), CK (green), and DAPI (blue) and imaged using 
Zeiss i880 confocal microscope. CAF cells are indicated by SMA+ and DAPI+ 
nucleus, whereas CTC are indicated by CK+ and DAPI+ nucleus. Images 
shown are from (A) female breast cancer patient 123 and (B) male colon 
cancer patient 124. Scale bars are 25 µm. 
 
CAFs (SMA+) and CTCs (CK+) were enumerated from multiple different patients in 
order to determine whether there is a pattern to the number of CAFs in patient blood. 
Individual counts ± standard error of the mean can be seen in Table 4.1. While it was 
determined there was no set pattern, there was a trend of much higher numbers of 
CAF cells than CTC for all patients. 
 
 
 
 
A B 
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Table 4.1. cCAF and CTC Counts from Primary Human Cancer Blood 
Patient Cancer Type # CAF (SMA+) 
# CTC  
(CK+) 
CAF:CTC 
Ratio 
88 Cervical 705.0±43.0 40.0±0.0 17.6 
96 Prostate 105.7±15.7 25.0±8.1 4.2 
123 Breast 1295.5±288.0 9.4±9.4 138.0 
124 Colon 582.9±105.0 53.6±53.6 10.9 
 
4.3.2 CAFs were directly isolated from the whole blood of cancer patients 
In order to run genetic testing on cells, a relatively pure sample needs to be obtained. 
Until this point, all work to isolate and identify circulating CAF (cCAF) cells from 
human cancer patient blood has been indirect. We attempted to directly isolate CAFs 
from human blood using the MACS technology from MIltenyi biotech. Buffy coat 
fractions were isolated using density gradient centrifugation then labeled with anti-
fibroblast MACS beads. Fibroblast cells were positively selected using a magnetic 
column and eluted. Cells isolated were stained for SMA and CK to determine the type 
of cell isolated. Figure 4.3 shows that cells isolated from human blood are SMA+ CAF 
cells.  
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Figure 4.3. cCAF cells isolated from human cancer patient blood are SMA+. 
cCAF cells were directly isolated from whole blood of  cancer patients, stained 
and imaged using Zeiss i880 confocal microscope. This figure shows a 
representative image from patient 126 (cholangiocarcinoma). SMA staining is 
shown in red, DAPI is shown in blue, while CK was stained in green. Scale 
bars are 25 µm. 
 
4.3.3 CAF protect CTC from high shear forces 
Anoikis resistance is a main tenet of circulating tumor cells and must occur in order 
cells to metastasize. We hypothesized that the presence of stromal cells may increase a 
CTC’s chance of survival under these hostile conditions. In order to mimic the forces 
experienced by cells as they pass through the heart, CAF co-cultured with PC3 and 
PC3 cultured alone were exposed to a series of millisecond pulses of high shear force.  
As shown in Figure 4.4, the presence of CAF allowed for a higher retention of 
viability of the PC3 cells when compared to PC3 cells cultured and sheared alone.  
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Figure 4.4. CAF protect cancer cells from shear-induced death. PC3:CAF co-
cultures or PC3 cultured alone were subjected to millisecond pulses of 5290 
dyn/cm2. Viability after 24 hours was evaluated based on Calcein-AM staining 
of PC3 cells. Data is from n=3 experiments. No significant difference was seen 
in the samples based on a two-way ANOVA.  
 
4.3.4 Soluble factors secreted from CAF cells not sufficient to protect cancer cells 
from high shear forces 
In order to better determine the method of protection, PC3 cells grown in normal 
media and PC3 cells grown in conditioned media from CAF cultures were subjected to 
the same shear conditions as the co-cultured cells. As figure 4.5 shows, there is no 
significant difference between the viability of cells from the two different culture 
conditions.  
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Figure 4.5. Conditioned media from CAF cells not sufficient for providing shear 
resistance of cancer cells. PC3 cells grown in normal media and grown in 
media conditioned by mouse CAF cells were subjected to a series of 
millisecond pulses at 5290 dyn/cm2. Viability was evaluated after 24 hours 
based on Calcein-AM staining. Graph shows data from n=2 experiments.  
 
4.4 Discussion 
Cancer-associated fibroblasts have been greatly implicated in the progression and 
metastasis of cancer (22). CAFs are known to secrete various pro-invasive paracrine 
signals including TGF-β (23), stromal-derived factor 1 (SDF-1) (24-26), MMPs 
(19,20), and hepatocyte growth factor (HGF) (29). When exposed to these factors, 
cancer cells increased invasive phenotypes and underwent epithelial to mesenchymal 
transition (EMT) (23). Moreover, CAFs created tracks in ECM that allowed for cancer 
cell collective migration (30). Most of these studies have been conducted in vitro and 
the in vivo implications still need to be determined.  
In this study, we show that CAFs not only promote the invasive phenotype in cancer 
cells, but also physically migrate alongside cancer cells. This was previously shown in 
mice (12), but until recently had not been confirmed in human samples (13).  
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Many studies of circulating tumor cells (CTC) have recently centered on the 
expression of EMT and stem cell markers by CTC (31-34). A study by 
Balasubramanian et al showed circulating cells that expressed the mesenchymal 
marker vimentin (33). CAFs are also known to express vimentin (35). It is possible 
that studies have incorrectly identified cCAFs as mesenchymal CTCs. Moreover, the 
role of mesenchymal CTC and cCAFs have not been elucidated and the isolation 
techniques described in this study would allow for direct analysis of cCAF cells.  
CAFs also promote drug resistance in cancer cells due to the induction of cell-
adhesion mediated drug resistance (CAM-DR) (22). In this study, we showed that 
cCAFs can be found in clusters with CTC. This could potentially have important 
implications to the drug resistance of CTC. Additionally CAFs are known to express 
integrins and other adhesion molecules. CTC are believed to migrate via adhesive 
interactions with the endothelium, which involve integrin-based adhesive interactions 
(36). It is possible that the physical association of CAF and CTC cells within the 
bloodstream could provide an adhesive advantage and increase the probability of 
extravasation and thereby distant metastasis.  
In this study, we present the first study of CAF:CTC interactions under high shear 
conditions. We have previously showed different properties of cancer cells can be 
modulated by shear stress (37,21). Due to the shear conditions to which CTC are 
exposed to, it is important to study these cells under the same conditions in vitro; 
however the vast majority of CTC studies are conducted under static conditions.  
The influence of CAFs on cancer progression and metastasis has been well 
characterized in the primary and metastatic sites. While there is more to learn about 
 95 
these sites, very little is known about the importance of CAFs during metastatic 
transit. In this study, we present a novel isolation technique that successfully isolated 
cCAFs from patient blood. This technique could provide researchers with 
opportunities to study primary cCAFs both in vitro and ex vivo. 
We also showed the possibility that cCAFs can influence CTC survival under harsh 
shear conditions. While more investigation is needed, this finding could have major 
implications on drug delivery and targeting. cCAFs could provide a novel therapeutic 
target that could help prevent and decrease the impact of metastasis. 
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Chapter 5 
 
Surgical Adjuvant Administration of EST Liposomes Do Not 
Provide Therapeutic Benefit in Breast Cancer Model 
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5.1 Introduction 
Localized breast cancer is virtually curable with a five-year survival rate of 99%. 
However, the survival rate decreases to 25% when the cancer has metastasized 
distantly (1). Therefore the study of metastasis in breast cancer is of upmost 
importance. One of the most popular areas of translational metastasis research to date 
is circulating tumor cells (CTCs). CTCs are cells that break off from the primary 
tumor and disseminate into the vasculature in order to spread to distant parts of the 
body.  
Hematogenous metastasis is generally accepted to occur in a stepwise fashion. First, 
subsets of cells mutate to allow for a migratory phenotype and begin to break through 
the basement membrane of the primary tumor. Next, cells make their way into the 
blood stream, or lymphatic system, where they circulate until they encounter the ideal 
environment. Here, they adhere and roll along the surface of the endothelium until 
they receive the correct cues to extravasate out of the vasculature. In the metastatic 
site, cells begin to multiply and create micrometastases that go on to become full 
blown distant metastases (2).  
Only a very small percentage of CTC are able to complete the metastasis process and 
propogate metastases. Because of this phenomenon combined with the importance of 
metastasis in cancer mortality, significant resources have been invested into CTC 
research. While the first clinical evidence of CTC was discovered in a cadaever in the 
19th century (3), it wasn’t until the late 1990s/early 2000s that CTC became a 
significant research area. Many technologies have been developed for the detection 
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and enumeration of CTC including size-based filtration devices, microfluidic 
chambers, and magnetic separation techniques (4–11).   
CTC have been shown to correlate with progression-free survival (PFS) and overall 
survival (OS) at levels of ≥5 CTC in late-stage breast cancer and ≥1 CTC in localized 
breast cancer (12). Similar trends have been shown in lung, colon, and prostate 
cancers (13–15). The correlation of CTC levels and the changes to CTC level in the 
course of treatment have also been studied, though with varying results (16,17).  
Tumor resection remains the most widely used form of treatment for breast cancer. 
While the reduction in tumor burden is thought to decrease the flux and rate of CTC 
shedding (18,19), it has also been shown that the surgical process can introduce a 
bolus of CTC into the bloodstream, thereby accelerating the metastatic potential. In 
fact, a study done in a xenograft model showed that various diagnostic and therapeutic 
techniques commonly used for breast cancer treatment can in fact introduce additional 
CTC into the vasculature (20).   
One of the main tenets of cancer that allows it to metastasize is its ability to evade the 
immune system (21). Recently, researchers have developed therapeutics, terms 
immunotherapies, that work to combat and overcome the gained immunoevasion of 
cancer cells. Currently there are two main types of immunotherapies on the market; 
one set works to decrease cancer-directed immunosuppression, and the other increases 
the cytotoxicity of immune cells against cancer (22,23).  
In our lab, we developed the first immunotherapeutic drug targeting circulating tumor 
cells (CTC) within the bloodstream in hopes of preventing cancer metastasis (24). The 
drug consists of a bilayer liposome that has been functionalized with two proteins, E-
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selectin, an adhesion protein found on the surface of inflamed endothelium, and 
TRAIL, TNF-related apoptosis inducing ligand. It binds to the surface of leukocytes in 
the blood, allowing the leukocytes to present the therapeutic protein from the drug to 
circulating tumor cells (CTC). The drug killed over 95% of COLO-205 or PC3 cells 
spiked into healthy donor whole blood. Additionally, when introduced into the 
circulation of mice, followed by an infusion of 2 million cancer cells, the liposomes 
reduced the number of cells to less than 2000. Moreover, a large increase of apoptotic 
cancer cells were found lodged in the lungs of mice of liposome-treated mice 
compared to those treated with buffer or soluble TRAIL alone (24). We also showed 
the efficacy of the liposomes in treating prostate cancer in vivo.  In this orthotopic 
model, CTC count was over 90% lower in EST liposome treated mice compared to 
buffer control treated mice. Additionally, administration of EST liposomes reduced 
the primary tumor size as well as metastatic spread (25). 
In this study, we explored whether minimal treatment with liposomes could prevent 
metastases in a tumor resection mouse model. Mice were given liposome treatment 
perisurgically as well as one week pre- and/or post-surgery. While the minimal 
treatment protocol was not enough to prevent metastases in vivo, this was the first 
study to show the lack of toxicity of EST liposomes in immunocompetent mice.  
 
5.2$Materials$and$Methods$
5.2.1$Cell$Lines$and$Culture$4T1'and'COLO4205'cell'lines'were'purchased'from'the'American'Type'Culture'Collection'(ATCC).'Both'were'cultured'in'RPMI41640'media'supplemented'with'
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10%'fetal'bovine'serum'and'10%'penicillin4streptomycin'under'humidified'conditions'at'37°C'and'5%'CO2.'''
5.2.2$Primary$Tumor$Establishment$84wk4old'female'BALB/cJ'mice'weighing'19423g'were'obtained'from'Jackson'Laboratory.'50,000'4T14luciferase'cells'were'injected'subcutaneously'into'the'right'abdominal'mammary'gland'with'a'30G'needle.''Animals'were'housed'in'pathogen'free'conditions'at'the'Cornell'University'Transgenic'Mouse'Core'Facility'and'injections'were'performed'under'sterile'conditions.'The'Cornell'University'Institutional'Animal'Care'and'Use'Committee'approved'all'animal'procedures.''
5.2.3$Circulating$Tumor$Cell$(CTC)$Enumeration$Mice'were'kept'alive'until'they'died'naturally'or'showed'signs'of'distress,'including'immobility'of'extremities'or'greater'than'20%'loss'of'body'weight.'Mice'showing'signs'of'distress'were'euthanized'using'CO2.'Upon'death,'blood'was'collected'from'mice'via'cardiac'puncture'into'heparinized'tubes'using'heparinized'syringes.'Blood'was'diluted'in'Hank’s'Buffered'Saline'Solution'(HBSS)'and'layered'on'top'of'3'mL'Histopaque'1077'(Sigma4Aldrich).'Tubes'were'centrifuged'at'2000xg'for'15'minutes'using'no'brake.'The'buffy'coat'was'extracted'and'washed'using'HBSS'twice.'Residual'red'blood'cells'(RBC)'were'lysed'using'multi4species'RBC'lysis'buffer'at'a'dilution'of'1:100'and'washed'immediately'using'HBSS.'Cells'were'resuspended'in'serum4free'growth'media'
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and'cultured'in'37'°C'and'5%'CO2'overnight'on'glass'bottom'plates.'Cells'were'stained'with'anti4mouse'EpCAM'antibody'for'1'hour'at'room'temperature.'Plates'were'washed'and'cells'were'subsequently'stained'with'FITC4labeled'secondary'antibody.'Images'were'captured'of'30440'randomly'selected'areas'of'the'plate;'EpCAM4positive'cells'were'counted,'averaged,'and'scaled'for'the'entire'area'of'the'plate.'''
5.2.4$Bioluminescent$Imaging$To'track'the'progression'of'the'primary'tumor'and'metastatic'spread'of'the'breast'cancer,'mice'were'imaged'using'a'Xenogen'IVIS'machine'every'347'days.'150'mg'of'luciferin'was'injected'intraperitoneally'(IP)'10'minutes'prior'to'imaging.'Mice'were'anesthetized'initially'using'3.0%'isoflurane'until'unconsicious.'Mice'were'then'moved'into'the'imaging'apparatus'and'anesthesia'was'maintained'at'2.0%'using'a'nose'cone.'Images'were'gathered'using'an'exposure'time'of'145'seconds.'Upon'completion'of'imaging,'mice'were'returned'to'cages.'''
5.2.5$Tumor$Resection$At'14'days'post4tumor'cell'injection,'primary'tumors'were'resected.'Hair'from'the'resection'site'was'removed'using'Nair'hair'removal'cream'24'h'prior'to'surgery.'On'the'day'of'surgery,'mice'were'anesthesized'with'345%'isoflurane'and'kept'under'anesthesia'with'the'use'of'a'nose'cone'for'the'entirety'of'the'procedure.'Once'the'mouse'was'placed'on'the'surgical'table,'the'site'was'cleaned'
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with'iodine'and'ethanol.'An'incision'adjacent'to'the'tumor'was'made'with'a'15C'scalpel'blade'and'the'tumor'was'gently'teased'away'from'the'skin'with'forceps'and'removed.'If'the'tumor'would'not'separate'fully'from'the'skin,'additional'skin'was'removed'as'well.'Once'the'tumor'was'fully'removed,'the'incision'was'closed'using'7mm'wound'clips.'Wound'clips'were'removed'after'10414'days.'Upon'completion'of'the'surgery,'the'mice'were'moved'to'a'recovery'cage'with'a'warmer.'Mice'were'kept'under'close'observation'for'the'next'72'h'and'received'subcutaneous'(SC)'injections'of'2'mg/kg'ketoprofen'immediately'prior'to'surgery,'24'h'post4surgery,'and'48'h'post4surgery.'The'Cornell'University'Institutional'Animal'Care'and'Use'Committee'approved'all'animal'procedures.''
5.2.6$Liposome$Preparation$A'lipid'film'of'phosphatidyl'chlone'(PC),'sphingomyelin,'cholesterol,'and'DOGS4nickel'NTA,'(50%:30%:10%:10%)'is'prepared'under'vaccum'for'18'h.'The'film'was'resaturated'in'buffer'at'50°C'then'subjected'to'10'freeze4thaw'cycles.'The'homogenous'lipid'solution'was'then'extruded'through'200'nm'filter'20430'times,'followed'by'a'100'nm'filter'20430'times.'Resulting'liposome'solution'was'degassed'under'N2'gas'for'up'to'5'minutes'followed'by'20'min'under'vacuum.'Liposomes'were'then'sterilized'by'autoclave.'The'surface'of'sterile'liposomes'were'functionalized'with'250'nM'recombinant'human'TRAIL'and'71.4'nM'recombinant'human'E4selectin'for'15'minutes'at'37°C using his-tag technology 
and then stored at 4°C.  
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5.2.7 Liposome Treatment  
 
In order to test the efficacy of novel E-selectin/TRAIL (EST)-functionalized 
liposomes on the progression of mouse metastases, mice were injected with 120 μL of 
liposomes, liposome buffer, or soluble TRAIL (sTRAIL) through the tail vein. Mice 
were randomized into 5 groups based on intensity of BLI imaging on day 7 as well as 
by animal weight. Groups 1-3 were given four doses, beginning when the tumor is 
palpable (day 7), while groups 4 and 5 received three doses, beginning 24 h prior to 
surgery. The entire dosing schedule is shown below (Figure 5.1), where the blue line 
indicates tumor cell injection and the red line indicates tumor resection. 
 
5.2.8$Weight$
Figure 5.1. Treatment Schedule for Surgical Adjuvant Administration of 
EST Liposomes. Numbers indicate days post-injection. Blue line is 
representative of tumor cell injection and red line is indicative of tumor 
resection date. Black lines indicate liposome administration.  
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In'order'to'monitor'the'health'of'the'mice'and'the'toxicity'of'the'treatment,'the'mice'were'weighed'at'least'once'a'week,'usually'coinciding'with'BLI'imaging.'As'the'health'of'the'mice'began'to'decline,'the'mice'were'weighed'every'243'days.'''
5.2.9$Histology$Upon'death'or'euthanasia,'the'mice'were'dissected'and'the'lungs,'kidneys,'stomach,'spleen,'liver,'as'well'as'any'additional'metastatic'nodules'were'removed'and'weighed.'Organs'were'trimmed'and'fixed'for'48'h'in'4%'paraformaldehyde.'Thin'sections'of'organs'were'made'and'stained'for'hemotoxin'and'eosin'(H&E).'The'stained'slides'were'evaluated'by'a'veterinary'pathologist'to'evaluate'progression'and'state'of'the'disease'in'each'animal.'''
5.2.10$Liver$Enzyme$Measurement$Liver'toxicity'is'a'major'problem'for'TRAIL'therapies'in'clinic.'We'evaluated'liver'toxicity'by'measuring'aspartate'aminotransferase'(AST)'and'alanine'aminotransferase'(ALT)'levels'within'mouse'plasma.'AST'and'ALT'levels'were'measured'using'BioVision'colorimetric'assay'kits'according'to'manufacturer’s'procedures.'''
5.3 Results 
5.3.1 4T1 mouse model tumor progression and CTC onset time established 
50,000 4T1-luciferase cells were injected subcutaneously into the mammary fat pad of 
8-week BALB/cJ mice. At pre-determined time intervals, 5 mice were sacrificed and 
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blood was drawn and pooled. Buffy coat was isolated and stained for the presence of 
CTC. Additionally, the growth of tumors was tracked using bioluminescent imaging 
(BLI). CTC were observed after 7 days. Tumors were first palpable at 7-10 days and 
of resectable size around 14 days. Figure 5.2 shows a progression of tumor growth.  
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Figure 5.2. Tumor progression of subcutaneous injection of 4T1 cells in BALB/cJ mice. 
50,000 4T1-luc cells were injected into mammary fat pad of 8-week BALB/cJ mice. 
Tumor progression was tracked using BLI. A) 7 days B) 10 days C) 14 days D) 17 days 
E) 21 days post-injection. Scale bar shows flux intensity in p/s/cm2/sr.  
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Figure 5.3. Tumor volume increased over time. Tumor length and width were 
measured using calipers. Tumor volume was calculated using Equation 5.1. 
Data represents average of n=4 mice. Error is error of the mean. Significance 
was tested using unpaired, two-tailed t-tests, but no significance was shown.  
 
Tumor volume over time was calculated based on caliper measurements taken at time 
of imaging using the following equation: !"#$%!!"#! !!! = !! ! ∗!!                                                                           (5.1) 
Tumor volume calculations are shown in Figure 5.3. No signif icance between the 
time points was shown using unpaired two-tailed t-tests (Day 14-17 p=0.4; Day 14-21 
p=0.15; Day 17-21 p=0.2), but the data did trend to greater tumor volumes over time.  
Upon sacrifice, blood was extracted from mice using cardiac puncture. Buffy coat was 
isolated and cultured for 7-10 days to allow for the death of leukocytes. Cells were 
then fixed and stained for EpCAM in order to detect CTC. CTC were detected in 
every sample. Representative images are shown in Figure 5.4.  
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Figure 5.4. Mouse blood contains CTC and cCAF cells. Buffy coat isolated 
from mouse blood was stained for EpCAM (green), smooth muscle actin (red), 
and DAPI (blue). Slides were imaged using Zeiss i880 confocal microscope. 
Representative images from A) 7 days B) 13 days post-injection are shown. 
Scale bars are 25 µm. 
 
5.3.2 Widespread metastases established in mice even following tumor resection 
In order to determine whether mice grew metastases after tumor resection 50,000 4T1-
luc cells were injected into the mammary fat pad of BALB/cJ mice and tumors were 
resected after 14 days. Tumor progression was tracked using BLI imaging (Figure 
5.5). Additionally, tumors were weighed upon resection and survival time was 
recorded. Primary tumors weighed an average of 93.5±30.7'mg.'Mice'survived'an'average'of'40.1±1.2'days'post4injection'(26.1±1.2'days'post4resection).' 
 
A B 
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Figure 5.5. Metastases evident after tumor resection. 50,000 4T1-luc cells were injected 
subcutaneously into the mammary fat pad of BALB/cJ mice. Tumors were resected on 
day 14 and subsequent metastatic growth was observed by BLI. A) 7 days B) 14 days C) 
28 days ventral view D) 28 days dorsal view E) 35 days ventral view F) 35 days dorsal 
view G) 41 days ventral view H) 41 days dorsal view. Scale bar shows flux intensity in 
p/s/cm2/sr.  
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5.3.3 EST liposome treatment provided no survival benefit 
Mice were injected with 50,000 4T1-luc cells and tumors were allowed to develop. 
Mice were divided into 5 groups and treated using the timeline described previously 
(Materials and Methods). Groups are shown in Table 5.1 below. 
 
Table 5.1. Group Treatment types 
Group Treatment 
1 Liposome Buffer 
2 Early sTRAIL 
3 Early EST Liposomes 
4 Late sTRAIL 
5 Late EST Liposomes 
 
Tumors were resected after 14 days and subsequent tumor and metastases growth was 
tracked over time with BLI (Figure 5.6). The total flux from BLI images was 
calculated using Living Image software (Figure 5.7). At day 35, the BLI flux for the 
buffer group peaked and was shown to be significantly different than both EST 
liposome groups using two-way ANOVA. The endpoint analysis for this study was 
overall survival (OS). While there were some differences in BLI intensity, no 
difference was seen in the survival curves between the groups (Figure 5.8).  
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7   14     17      21      28   35      42 
7  14    17        21      28     35       42 
D 
E 
Figure 5.6. Tumor progression independent of treatment. The spread of metastases after 
tumor resection under different treatment conditions was tracked using BLI. Representative 
images from groups A) 1 B) 2 C) 3 D) 4 E) 5 are shown. Numbers indicate number of days 
post-injection when images were captured. Scale bar shows flux intensity in p/s/cm2/sr.  
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Figure 5.7. Quantitative analysis of BLI images. Total flux from BLI images of 
each mouse was calculated using Living Image software. The mean (n=6-8) 
was graphed and error is shown as standard error of the mean. Significance 
was determined using two-way ANOVA. * p<0.05, ** p<0.01  
Figure 5.8. EST liposome treatment shows no survival advantage. Mice were 
closely monitored after tumor resection and adjuvant treatment. Day of 
death/euthanasia was recorded and survival curves are shown. There was no 
significant difference between the curves from any treatment.  
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Figure 5.9. Organ weights showed some difference compared to healthy controls. 
Upon death/resection, organs were removed and weighed. Average weights were 
compared to healthy control mice that received no treatment or tumor cell injection. 
Significance was determined using a one-way ANOVA. * indicates p< 0.05, ** 
indicates p<0.01.  
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5.3.4 Injection of EST liposomes showed no toxicity 
We previously showed that EST liposome treatment caused no detectable toxicity in 
immunocompromised mice (25). This is the first study to administer EST liposomes to 
immunocompetent mice. We hypothesized that we would also not detect any toxicity. 
BALB/cJ mice with no tumors were treated following the same treatment procedure as 
outlined above. One week after the last dose, mice were sacrificed and subjected to a 
number of toxicity tests. Organs were harvested and weighed. Organ weights showed 
no significant difference based on treatment (Figure 5.10). Blood plasma was isolated 
and tested for liver enzyme levels. Again, no significant difference was seen between 
treatment groups (Figure 5.11). Lastly, we followed the animal weight of mice in 
experimental groups for the same time period as toxicity study. While there was 
significant difference between the early EST liposome treatment group and the buffer 
treatment group, there was no difference between starting and ending weights of any 
of the treatment groups (Figure 5.12). 
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Figure 5.10. No significant difference in organ weights between treatment 
groups. Mice with no tumors were treated using same protocol as 
experimental groups. One week after final dose, mice were sacrificed and 
organs were harvested and weighed. Data shown is average ± standard 
deviation (n=2). Significance was determined using two-way ANOVA.  
 
Figure 5.11. EST liposome treatment caused no significant difference in liver 
enzyme measurements. TRAIL is known to be toxic to hepatocytes. In order to 
determine liver health, plasma levels of aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) were measured in mice treated with liposome 
buffer, sTRAIL, or EST liposomes. sTRAIL was shown to have significantly 
higher levels of ALT than both buffer and liposomal treatment. AST levels did 
not change with any treatment. Data is representative of n=2-3 replicates with 
error bars of standard deviation. ****p<0.001.  
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Figure 5.12. Animal weight stayed consistent over treatment. Animal weight 
was tracked over tumor growth/resection/treatment. Data shown is average of 
n=6-8 animals, with error represented by standard deviation. Significance was 
determined using two-way ANOVA where ** is p<0.01.  
 
5.4 Discussion 
Cancer metastasis accounts for 90% of all cancer fatalities (1), but the vast majority of 
cancer therapeutics target the primary tumor. We recently presented work on the first 
therapeutic that directly targets circulating tumor cells (24). The therapeutic works by 
adhering to circulating leukocytes that then interact with CTCs, bringing them in 
contact with TRAIL proteins on the surface of the drug. The liposomes eliminated 
over 95% of CTC in vivo. Here, we present the first study of EST liposomal treatment 
in combination with tumor resection.  
Recombinant TRAIL therapies have been limited in the clinical setting due to 
hepatocyte toxicity caused by aggregation of TRAIL proteins. His-tagged TRAIL in 
particular has been shown to create supramolecule aggregates (26,27). In this study, 
we used recombinant TRAIL, but these EST liposomes presented no toxicity in 
immunocompetent mice reflected by no decrease in weight (Figure 5.12) or 
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discrepencies in organ weights (Figure 5.10). Moreover, there was no noticeable 
hepatocyte toxicity indicated by a lack of difference in liver enzyme levels between 
the control and treatment mice (Figure 5.11). The lack of toxicity is likely because the 
TRAIL molecules are bound to the liposomal membrane and therefore unable to 
aggregate. Other approaches to combat TRAIL toxicity include the creation of fusion 
proteins using small chain variable fragments (scFv) directed towards cancer cells or 
immune cells (28). This approach holds promise with our current strategy as well. We 
are currently exploring the creation of an E-selectin/TRAIL fusion protein. This would 
potentially minimize the variability of therapeutic from lot to lot. Additionally, the 
shelf life of the therapeutic may be increased due to the oxidation potential of 
liposomes.  
While the therapeutic showed great promise on the toxicity side, the therapeutic 
advantage was not as pronounced. In this study, we explored how perisurgical 
administration of liposomes impacted the metastatic spread of breast cancer after 
tumor resection. EST liposomes did provide decreased metastatic burden at one time 
point when compared to mice treated with buffer control (Figures 5.6, 5.7), but EST 
liposome treatment also provided no survival benefit (Figure 5.8). This is the first in 
vivo study involving EST liposomes that showed no therapeutic benefit (24,25). It is 
believed that the lack of benefit may be due to the short administration timeline of 
therapy. When used to treat prostate cancer, the liposomes were administered every 3 
days for a total of 6 weeks. We hypothesize that with a less minimal therapy schedule, 
therapeutic advantage may be seen in the tumor resection model.  
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EST liposomes may hold promise as a cancer therapeutic. This is the first therapeutic 
that directly targets CTC and has been shown to eliminate over 90% of CTC in vivo as 
well as decreased metastatic burden in a prostate xenograft model (25). Here, we 
showed that while minimal administration of EST liposomes perisurgically does not 
increase OS, liposomes do not cause toxicity in immunocompetent mice. More studies 
need to be conducted before the full clinical utility of EST liposomal therapy can be 
evaluated.  
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Chapter 6 
 
Conclusions and Future Directions 
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6.1 Concluding Remarks 
Cancer research has been greatly improved in recent history by the adaptation of 
techniques, which reflect the real-life organization and heterogeneity of the disease. 
Instead of studying 2D cultures of purely cancerous epithelial cells, researchers now 
work in 3D orientations and incorporate a variety of supporting cells into cancer 
experiments. Most of this work though focuses primarily on primary tumors and solid 
metastases. Work on the transitional metastatic state, namely circulating tumor cells, is 
still in its infancy.  
To date, CTC research has made great strides in identifying markers for subsets of 
CTC (1–5), relating prognosis to CTC count (6,7), and drawing conclusions on 
therapies and surgical techniques due to changes in CTC numbers (8–11). In Chapters 
2 and 3, we added to this wealth of knowledge by introducing a unique broad 
application diagnostic for drug screening using peripheral blood treatment and 
subsequently showing that primary CTC can be killed by TRAIL-therapeutics. These 
studies also present some of the first studies of CTC in situ. Most CTC work is 
performed on isolated CTC, which may give false positives due to the harsh nature of 
isolation.  
Just as the interaction between epithelial tumor cells and supporting cells, such as 
stromal and immune cells, is pivotal for the progression of primary tumors, in order 
for CTC to survive and successfully metastasize, they must interact with various cell 
types within the vasculature (12). Many hematogenous metastasis studies have 
explored the adhesive interactions between CTC and the endothelium (13–17). 
Recently, these adhesive events were confirmed using primary CTC from peripheral 
blood (18). The interaction between CTC and immune cells are also of upmost 
importance. We previously showed that this interaction can be used for therapeutic 
advantage by developing an immunotherapeutic that binds to the surface of leukocytes 
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and induces apoptosis upon immune cell:CTC binding (19). In Chapter 4, we 
introduce another CTC:supporting cell interaction that may play a role in metastasis. 
We showed that cancer-associated fibroblasts migrate with CTC in primary human 
blood. This work also introduced the first isolation technique to directly isolate cCAF 
from peripheral blood. Because of the heterogeneity of CAF in primary tumors (20), 
the direct study of cCAF is important to fully understanding their impact on metastasis 
and tumor progression. This isolation technique will allow for extensive 
characterization of the protein and gene signatures of cCAF.  
 
6.2 Future Directions 
 
The work presented in this paper introduced a number of new techniques for studying 
metastasis using circulating tumor cells. First, we introduced a novel diagnostic 
platform proposed to identify drug sensitivity prior to administration. The study 
presented here was merely a proof of concept. In order for the clinical utility of this 
technique to be confirmed, a matched study could be performed that would directly 
predict the drug sensitivity of patients, which could then be compared to the clinical 
response of the patients to the drug. 
We also presented a technique to isolate cCAF from human blood. While it has 
extensively been shown that cCAF contribute to many areas of tumor progression 
including invasion, angiogenesis, immune evasion, and growth (21), the direct effect 
these cells have on cancer cells in the bloodstream has not been shown. Here we 
presented an initial study showing cCAF may protect CTC from high shear conditions. 
The direct mechanism of this action is currently being studied. Additionally, the effect 
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of cCAF presence on drug sensitivity under shear conditions, namely TRAIL 
sensitivity of CTC is also being studied.  
cCAF presence may have a direct effect on the effectiveness of our EST liposomes as 
well. This will be explored in the future. Additionally, the functionalization of the 
liposomes could be altered to target cCAF using antibodies against fibroblast 
activation protein (FAP) or platelet derived growth factor-α/β.  
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Appendix A 
 
Commentary on Therapeutic Targeting of Circulating Tumor 
Cells 
 
Portions of this appendix were adapted from: Marshall'JR,'King'MR.'Therapeutic'Targeting'of'Circulating'Tumor'Cells:'An'Important'Problem'That'Deserves'Careful'Study.'Cell'Mol'Bioeng'[Internet].'NIH'Public'Access;'2015'Dec'[cited'2016'Oct'20];8(4):527–9. 
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In cancer research, the discovery and study of circulating tumor cells (CTCs) has 
seemed to open a world of possibilities. We now have the potential to gain 
understanding of individual cases of metastatic cancer without invasive procedures. 
This area of research is, however, not without some basic pitfalls. In this commentary, 
we address some of these pitfalls by discussing two recent examples in the published 
literature and discuss ways to overcome their limitations in the hopes of educating 
those who may be entering the growing field of CTC research. Careful research design 
should always be followed to prevent incomplete or misleading studies from entering 
the literature, and thereby avoid setting back this burgeoning field. 
Two recent CTC papers appearing in the journal PLOS ONE can serve as examples of 
preliminary studies lacking the necessary controls to yield meaningful results. In the 
first, Kim and Gaitas outline a creative application of photodynamic therapy (PDT) 
intended to prevent cancer metastasis, in which tubing could be attached to a patient’s 
vasculature to divert blood into an external device where it would be exposed to LED 
illumination to induce cancer cell death 5. The illumination, combined with a 
photosensitizer conjugated to an antibody to CD44, a cell adhesion protein found on 
many cancer cells, is intended to eliminate CTCs in the blood. This study attempts to 
examine the feasibility of this technique in vitro. Upon first reading the results of the 
paper might seem promising, with the vast majority of prostate cancer cells spiked into 
whole blood dying within an hour after treatment; however, the authors overlooked 
key aspects of treatment in blood that, when considered, significantly weaken the 
overall impact of the paper.  
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When critically evaluating this proposed therapy, one must first look at the feasibility 
of treating the entire blood volume in a realistic time frame. Limitations of throughput 
are a common issue in proposed CTC technologies. Most devices test a small volume 
of blood and while the information gleaned from this volume can be of scientific 
interest 4,10,14,15, the scale-up of such a device becomes more complicated. The scale-up 
of the PDT device to treat an adult blood volume (~5L) in this case does seem 
feasible, however. One may calculate that at a physiological blood velocity typical of 
diameter of the 1 mm internal diameter tubing used (~30 cm/s), 36 meters of tubing 
would be needed to achieve their prescribed 2 min of LED light exposure and thus the 
entire blood volume could be processed within about 6 hours. This amount of tubing 
would contain a blood volume of 28 mL, also feasible. A single or double layer of this 
tubing could, in theory, be arranged in a small bedside or even portable extracorporeal 
device. Unfortunately no analysis of this form was discussed in the 2015 paper 
presenting the technology5. 
Importantly, one must also consider the proposed therapy’s effect on the normal blood 
cells, which would likewise also receive exposure to the photodynamic sensitizer and 
light source. This is most problematic issue with the proposed technology. The authors 
chose CD44 as the molecular target for the photosensitizer therapy. While CD44 
expression is well documented in cancer 3,6,7,11, it is also a major adhesion molecule for 
leukocytes 8,18. CD44 is also known as phagocytic glycoprotein-1, and is a receptor for 
hyaluronic acid. The implication of this, of course, is that while the photosensitizer 
may target CTCs, leukocytes will almost certainly become bound to the sensitizer and 
also killed during light treatment. Furthermore, even if a more appropriate antigen was 
 146 
selected to better avoid off-target binding, the reactive oxygen species (ROS) 
generated by the therapy would still be likely to effect surrounding blood cells and 
accumulate within the plasma during the course of treatment. The authors state that the 
diffusion distance of ROS is small (~100 nm, reportedly) and that ROS  generated on 
the surface of CTCs should not reach neighboring blood cells, and while this might 
hold true under static conditions, under dynamic blood flow conditions it is the much 
greater convective length scale that must be considered when estimating whether ROS 
generated in the vicinity of one cell surface may affect neighboring cells. The chaotic 
mixing of bulk blood flow nearly ensures that all cells within the peripheral blood 
flowing through the device will be equally exposed to extracellularly generated ROS. 
Remarkably, Kim and Gaitas demonstrated the ability to kill PC-3 cancer cells within 
spiked blood samples, but never measured whether the PDT approach was also killing 
blood cells at the same rate, a minimum requirement of any selective therapy designed 
to act in the bloodstream 5. In our opinion, this important control measurement should 
be a necessary precursor to publication in a peer-reviewed research journal, and the 
absence of basic measurements such as these cast the overall conclusions into 
considerable doubt. The authors used the loss of fluorescence signal from PC-3 
prostate cancer cells labeled with the live cell dye CellTracker as their sole measure of 
cell death, whereas an additional assay of apoptosis and necrosis such as Annexin V, 
TUNEL , or MTT is recommended. 
Finally, whenever light is used to induce a cellular response, one must also be 
concerned with the effects of heating. This is particularly important in the blood since 
red blood cells will undergo lysis at temperatures above 45 degrees Celsius 2. 
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Anywhere from 60-95% of the energy of LEDs is converted to heat. This heat is 
generally believed to not be given off as infrared heat and therefore may not affect the 
sample directly 17. However, there have been reports of IR heat production and 
resulting sample heating by LEDs, an effect that is dependent on the power used and 
the type of heat sink 12. It may thus be possible to avoid this issue through careful 
engineering, but heating should still have been considered and tested in the paper (it 
wasn’t).  All of the PDT experiments of Kim and Gaitas were performed in a foil-lined 
Styrofoam insulated cooler, using sealed, static well plates and blood-filled tubing 
sealed on both ends. Despite the diagram of their Figure 1, no flow experiments were 
performed 5. 
The majority of current CTC research focuses on the isolation and enumeration of 
cells captured from patient blood samples for analysis. While this work does not 
directly involve the toxicity of reagents on either cancer or blood cells, it nevertheless 
holds its own pitfalls and issues that, if are not properly addressed, can skew results 
and thereby lead to misleading conclusions.  
One example of this is another paper by Gaitas and Kim published recently in PLOS 
ONE 1. The authors present a method for isolating CTCs in a microtube device coated 
with antibody against epithelial cell adhesion molecule (EpCAM). The authors 
showed that they were able to capture 85% of EpCAM-expressing cancer cells 
suspended in buffer, and 44% of the cancer cells from whole blood  spiked with 
cancer cells. While this method shares similarities with other EpCAM-antibody 
isolation approaches previously described in the literature 4,13,15,16, the basic idea 
presented is straightforward and would likely not encounter major challenges. 
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However, as with the previously discussed paper by Kim and Gaitas, some much 
needed control experiments and other considerations were neglected, seriously 
compromising the soundness of the study. 
First, the device is presented as a dynamic microfluidic device intended to capture 
cells from the bloodstream of patients to achieve a therapeutic filtering of the blood, 
however the only experiments performed in the study were under static (i.e., no flow) 
conditions. It is likely that the addition of shear force would affect the capture 
efficiency of the device and this is something that should have been addressed to 
support the conclusions of the paper. 
Second, the authors again failed to take the blood cells into consideration. In other 
CTC isolation studies, the capture purity as well as the capture efficiency is reported 
4,9,14. This is important for two reasons. First, if too many white blood cells adhere to 
the device, they will block the capture of further cancer cells, thereby decreasing the 
capture efficiency. This is especially important for the device discussed in the Gaitas 
and Kim paper, as they are suggesting that this technology could be used as a blood-
filtering device for metastatic cancer patients. Such a device would process many 
more white blood cells than cancer cells, and over time the device would likely 
become less and less efficient due to nonspecific adhesion of leukocytes. The purity is 
equally important for post-isolation processing. Certain techniques that involve DNA 
and RNA analysis require very pure samples to detect cancer-associated mutations 
without excessive contamination from blood cell genetic material. For these reasons, 
the achieved purity is always reported for new CTC isolation devices. 
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We were quite surprised that Gaitas and Kim only reported the number of cancer cells 
captured by their antibody-coated tubing and did not attempt to assess the number of 
leukocytes captured, either qualitatively with a bright field or phase contrast 
micrograph to accompany the fluorescence image showing EpCAM+ capture, or 
quantitatively using a hemocytometer or flow cytometer. We are even more surprised 
that such a preliminary effort would be accepted for publication in a reputable journal 
such as PLOS ONE. Surely a study whose abstract’s first sentence promises a “tube to 
selectively capture circulating tumor cells” should show some measure of selectively 
within its pages? Perhaps the bright field images showed a degree of indiscriminate 
cell capture which contradicted the stated goals of the study. 
As the title of this commentary states, the development of new technology to study 
(and treat) circulating tumor cells is sorely needed, but it must be carried out with 
sufficient rigor to advance the field. Authors, reviewers, and editors should work 
together to avoid flooding the literature with hastily done, inadequate work that can 
act more to mislead and confuse rather than enlighten. We also hope that our 
commentary can serve a more productive purpose than simply singling out one 
laboratory that is new to the CTC field, by pointing out some of the common pitfalls 
and necessary considerations for researchers to be aware of. Overall, we are 
encouraged that the field of CTC research is growing and that more innovative ideas 
are being proposed, such as blood-filtering devices and new CTC-targeted therapies. 
These ideas are vital for the advancement of cancer metastasis research and treatment. 
By addressing common issues such as those presented in this commentary, we believe 
that CTC research can become a more important area of cancer investigation. We hope 
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those who are just entering the field can draw inspiration and advice from this 
commentary and we look forward to seeing what technologies the next wave of CTC 
research will bring.  
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Appendix B 
 
Commentary on Circulating Tumor Cells and Surgical 
Intervention 
 
Portions of this appendix were adapted from: Marshall'JR,'King'MR.'Surgical'intervention'and'circulating'tumor'cell'count:'a'commentary.'Transl'Cancer'Res.'2016;5(1):S126–8.
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Surgical resection of tumors is a common practice in breast, lung, melanoma, and 
many other cancers, and is known to extend life expectancy significantly. However, 
recurrence and metastasis are still frequently seen post-resection. Distant metastasis 
occurs when cells from the primary tumor enter the bloodstream, adhere to the 
endothelium, infiltrate a distant site and proliferate. The number of circulating tumor 
cells (CTCs) in the vasculature has been shown to correlate with patient survival and 
prognosis(1). CTC count perioperatively has been under investigation to determine 
whether surgical procedures introduce additional CTCs into the bloodstream. While 
this postsurgical CTC increase has been observed for various cancer types, many 
studies have shown that CTC counts normalize and often decrease after surgery(2). 
Still, the long-term effects on progression and survival of surgical release of CTCs 
have not been definitively determined. In this commentary, we discuss the prospect of 
minimizing surgical CTC increases using less invasive techniques as well as the need 
for more aggressive perioperative targeting of CTCs.  
While the first CTCs were observed in the 1800s(3), the importance of CTC presence 
in cancer and its potential impact in cancer treatment have only recently been 
recognized. Early CTC research focused primarily on the isolation and enumeration of 
CTCs in different cancer types. Currently, studies have expanded to include the 
exploration of the use of CTCs in early diagnostic tests(4) as well as the development 
of anti-metastatic therapeutics(5–7).  
 
One area of research that may have far reaching implications in cancer treatment is the 
relationship between surgical technique and CTC count. Many studies have shown 
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that common methods used for diagnosis (biopsy) and treatment (resection) of cancer 
can lead to bloodborne tumor cell dissemination. In one study, The Zharov lab showed 
that while mechanical palpation of breast tumors did not increase CTC counts in mice, 
tumor biopsy and resection did(8). Moreover, lung resection was shown to increase 
CTC count, where the presence of CTC clusters correlated with worse prognosis(9). 
Bayarria-Lara et al. show that CTC counts decrease one month after lung resection, 
though the presence of CTC after surgery was associated with early recurrence(10).  
 
In a recent study published in Investigative Urology(11), Kauffman and associates 
investigated whether robotic assisted laparoscopic radical prostatectomy (RALRP) 
reduced CTC introduction in comparison to past studies conducted on open 
prostatectomy. They showed that RALRP did not significantly increase CTC numbers 
in patients, whereas past studies of open prostatectomy based on RT-PCR 
amplification of epithelial markers in blood were consistent with CTC increases. In the 
study, blood samples were drawn from 25 patients preoperatively as well as 
intraoperatively. Using EpCAM-positive selection, 48% of patients were shown to be 
CTC-positive preoperatively while 52% of patients were CTC-positive after 
surgery(11). Perioperative increases and decreases in CTC count were observed at the 
same frequency, and increases were found to never exceed 1 CTC per 8 mL blood(11). 
It is suggested that RALRP may hold an advantage to open prostatectomy due to the 
lack of CTC introduction(11).  
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Similar results have been obtained in studies focused on other cancer types. In 
esophageal cancer, minimally invasive esophagectomy showed lower intra- and post-
operative CTC counts than open esophagectomy(12). Video-assisted lobectomy also 
yielded fewer CTCs than open thoracic surgery for the resection of lung cancer(13). 
However, the impact of the additional CTCs introduced is debated. Several reports 
have demonstrated a correlation between increased CTC numbers postoperatively and 
worse prognosis in lung, colon, and stomach cancers(14–16), while one study in 
pancreatic cancer shows no such relationship(17). In fact, reports show that the 
increase of CTC after surgical procedures normalizes over time, sometimes resulting 
in lower CTC counts than preoperatively(2,8,10,18). The eventual fate of these 
observed CTCs is of course unknown. Reports of this nature compel the need for 
further analysis of the correlation between surgical technique and cancer progression. 
In addition, methods to decrease CTC frequency during surgery should be 
investigated, including therapeutic agents to target CTCs.   
 
Most methods for cancer treatment focus on the eradication and shrinking the primary 
tumor, even though 90% of cancer fatalities arise from metastasis. Recently, our group 
developed a therapeutic approach that directly targets CTCs(19). This nanomedicine 
construct is comprised of phosphatidylcholine liposomes conjugated with E-selectin, a 
natural endothelial adhesion molecule, as well as TNF-related apoptosis-inducing 
ligand (TRAIL), a pro-apoptotic ligand whose receptors are upregulated on many 
cancer cells. The drug acts by adhering to leukocytes or other immune cells within a 
patient’s blood. These cells then interact with CTCs, inducing apoptosis through 
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TRAIL signaling(19). In pre-clinical studies, E-selectin/TRAIL liposomes were shown 
to significantly reduce CTC number in colon and prostate cancer models. When 
introduced into the bloodstream of mice containing colon cancer cells, the TRAIL 
liposomes decreased CTC count by over 90%(19). In an orthotopic prostate cancer 
model, CTC counts were found to be 94% lower in mice treated with ES/TRAIL 
liposomes compared to control mice(7). A therapeutic of this type could hold great 
promise as an adjuvant treatment when used perioperatively, by preventing the 
operative increase of CTCs and therefore any adverse downstream effects.  
 
While CTC count surrounding surgical procedures has not been directly implicated in 
metastasis, it is hypothesized that the introduction of CTCs during surgery may 
promote cancer progression. This motivates further research to elucidate the 
correlation between type and timing of surgical intervention, and cancer progression. 
Moreover, since over 90% of cancer fatalities result from metastasis, a greater 
emphasis on treatments that target CTCs or disseminated tumor cells is also warranted. 
It is possible that by minimizing the surgically-induced CTC burst through minimally 
invasive surgical techniques, as well as by targeting CTCs perioperatively, we may 
one day decrease the occurrence of metastasis and achieve improved patient outcomes. 
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